



(86) Date de dépôt PCT/PCT Filing Date: 2001/11/16
(87) Date publication PCT/PCT Publication Date: 2002/05/23
(45) Date de délivrance/Issue Date: 2010/10/05
(85) Entrée phase nationale/National Entry: 2003/05/13
(86) N° demande PCT/PCT Application No.: GB 2001/005061
(87) N° publication PCT/PCT Publication No.: 2002/040678
(30) Priorité/Priority: 2000/11/17 (GB0028130.3)


(51) Cl.Int./Int.Cl. *A61K 38/16* (2006.01),
A01N 63/02 (2006.01), *A01P 1/00* (2006.01),
A61K 48/00 (2006.01), *A61P 31/04* (2006.01),
C07K 14/195 (2006.01), *C07K 14/32* (2006.01),
C07K 14/33 (2006.01), *C12N 15/31* (2006.01),
C12N 7/01 (2006.01), *A61K 38/00* (2006.01)

(72) Inventeur/Inventor:
FAIRHEAD, HEATHER MARIE, GB

(73) Propriétaire/Owner:
PHICO THERAPEUTICS LTD., GB

(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : PETITE PROTEINE DE SPORE SOLUBLE DANS L'ACIDE (SASP) ET UTILISATIONS DE CELLE-CI
(54) Title: SMALL ACID-SOLUBLE SPORE PROTEIN AND USES THEREOF



(57) Abrégé/Abstract:

In the field of medicine, regulation of cell growth is a fundamental concern. In particular, uncontrolled growth of microorganisms such as bacteria or fungi can be problematic or life threatening to a patient. The present invention provides a polypeptide having α/β -type SASP activity for use as medicament for inhibiting or preventing cell growth.

- 99 -

ABSTRACT

In the field of medicine, regulation of cell growth is a fundamental concern. In particular, uncontrolled growth of microorganisms such as bacteria or fungi can be problematic or life threatening to a patient. The present invention provides a polypeptide having α/β -type SASP activity for use as medicament for inhibiting or preventing cell growth.

- 1 -

SMALL ACID-SOLUBLE SPORE PROTEIN AND USES THEREOF

Field of the Invention

The present invention relates to polypeptides, polynucleotides and compositions thereof for use as medicaments, particularly to inhibit or prevent cell growth, such as bacterial cell growth.

Background to the Invention

Spore-forming bacteria form a relatively small class of bacteria which are capable of producing endospores. Endospores are dormant non-reproductive survival forms of the bacteria which are resistant to inhospitable environments such as high temperatures, harmful chemical agents and damage from UV light. These spore-forming bacteria comprise *Bacillus*, *Clostridia* and *Sporosarcina* species as well as one strain of *Thermoactinomyces* and other less common species of *Sporolactobacillus* and *Oscillospira*. During a process of sporulation a class of proteins known as the small acid-soluble spore proteins (SASP) are produced. SASP are acid-soluble and have low molecular weights of between 5 and 11kDa. SASP are reported to have two main roles within bacterial spores: firstly, they act to protect the spore DNA from damage from UV, heat, depurination and many potentially harmful chemical agents; and secondly, SASP provide a source of free amino acids upon spore germination, without which the newly vegetative cells cannot outgrow.

In *Bacillus* species there are three types of SASP known as α , β and γ type SASP. The amino acid sequences of α/β -type

- 2 -

SASP are highly conserved both within and between species (~70% identity and ~80% similarity, without gaps for *Bacillus* species). However these proteins show no sequence similarity to any other protein family and do not contain any motifs characteristic of other DNA binding proteins (Setlow, 1988). The α/β -type SASP are closely related immunogenically, have molecular weights of approximately 6.2-7.6 kDa and have a significant percentage of hydrophobic amino acids (up to 30%) (Setlow, 1988). The γ type SASP have a molecular weight of 8-11 kDa, are extremely low in large hydrophobic amino acids (<11%) and have a higher isoelectric points than the α/β type SASP from the same species (Setlow, 1988). In any given organism there are two major SASP of the α/β type, as well as many minor α/β type SASP, each encoded by a unique gene (Setlow, 1988). In contrast, all the organisms which have been examined have only one γ type SASP and its function is quite different to α/β type SASP, being used primarily to supply amino acids for outgrowth (Hackett and Setlow, 1987). A list of all the α/β type SASP which have been sequenced to date are given in Appendix 1, together with their related protein sequences. The extent of conserved amino acid residues between these protein sequences is shown in Appendix 2.

Various studies on SASP have focused on characterising the way in which the α/β type SASP protects DNA from UV damage. In one study (Setlow et al 1991) a gene (*sspC*) encoding an α/β -type SASP was inserted in a plasmid under the control of an inducible promoter to show that SASP cause DNA of a

- 3 -

vegetative cell to assume spore-like characteristics. It was observed that binding of α/β type SASP to *E.coli* DNA caused an increase in plasmid negative superhelical density suggesting a concomitant change in DNA structure. It is postulated that a change in conformation of DNA from B-like to A-like protects the DNA against UV light.

In the field of medicine, regulation of cell growth is a fundamental concern. Cell growth within the body is subject to strict control; this includes both the cells which comprise the body's tissues and organs as well as commensal bacterial cells such as the skin and gut flora. Uncontrolled growth of microorganisms such as bacteria or fungi can be problematic or life threatening to a patient. Common treatment for bacterial infections in particular, involves the use of conventional antibiotics which may have a broad spectrum of activity (such as penicillin) that usually work by targeting bacterial cell walls. Other classes of antibiotics act by inhibiting protein synthesis in the bacterial cell, although many of these also display varying levels of toxicity to human and other animal cells. Bacteria can readily become resistant to conventional antibiotics and "super resistant" strains are now emerging. Thus there is a clear need for alternatives to currently available antibiotics.

Under certain circumstances normal cells in the body's tissues or organs can adopt aberrant characteristics and undergo uncontrolled growth, leading to the disease cancer, which can be life threatening. Many of the current treatments for cancer involve the use of agents or drugs

- 4 -

which have toxic and/or unpleasant side effects. Some cancers also exhibit resistance to drugs or do not respond to other treatment regimes, thus alternative control measures are urgently needed.

Summary of the Invention

In a first aspect, the present invention provides a polypeptide having α/β type SASP activity, for use as a medicament.

It has surprisingly been found that the polypeptide of the present invention may be used as a medicament, particularly to inhibit or prevent unwanted cell growth such as cell growth which is pathogenic to a subject. Such cell growth includes growth by bacterial cells, and some eukaryotic cells such as fungal or cancer cells.

A polypeptide according to the present invention may comprise any peptide, oligopeptide, protein and may exist in monomeric or multimeric form with or without covalent modification such as post-translational modification including glycosylation. Typical polypeptides according to the present invention comprise the amino acid sequence:

mannnssnsnellvpgaeqaidqmkyeiasefgvnlgadttarangsvggeitk
rlvqlaeqqllgggtk (SEQ ID NO:1).

Preferably, the polypeptide comprises any one of the amino acid sequences shown in appendix 1 such as that encoded by the *sspC* gene from *Bacillus subtilis*, as shown in appendix 3. Any one of these polypeptides may contain mutations and/or deletions such as those produced by random mutagenesis or by site directed mutagenesis, which do not

- 5 -

substantially reduce the α/β type SASP activity thereof. Despite the high degree of sequence conservation between natural SASP proteins, significant differences in DNA affinities exist (Setlow et al., 1992). The potential exists to tailor SASP protein sequences to increase affinity of the protein for target DNA. On this basis it may be possible to utilise the natural variation in SASP or to engineer SASP to optimise targeting of different species of bacteria and/or desired genes within any given organism.

Generally, α/β type SASP activity may be measured by evaluating the effect of the polypeptide on DNA conformation. α/β type SASP activity may therefore be defined as the ability to convert DNA from a B-like conformation to an A-like conformation. This may be measured by any one of the following techniques.

(a) A reference for describing the change in conformation from B- to A-like is Mohr et al., 1991. Changes in circular dichroism spectra have long been regarded as sensitive criteria for DNA conformations and distinctions between the main families of secondary structure are unambiguous (Mohr et al., 1991). Interaction of both eukaryotic (calf thymus) DNA and prokaryotic DNAs with α/β -type SASP (in particular experiments using SspC from *B. subtilis*) induces spectroscopic features characteristic of A-DNA. Fourier-transform infrared (FTIR) spectroscopy provides an independent means of evaluating the conformational state of DNA complexed with α/β -type SASP. The FTIR spectra of concentrated solutions of calf thymus DNA show a principal absorption band at 1225 cm^{-1} which

- 6 -

arises from the antisymmetric O-P-O phosphate stretching vibration (Mohr *et al* 1991). This band shifts to 1246 cm^{-1} with SspC-calf thymus. Such behaviour is characteristic of a B- to A-transition, although it should be noted that hydration effects alone can also influence the position of this O-P-O stretching band. Therefore an additional indication of B- to A- transition can be used, comprising the appearance in the FTIR spectrum of the SASP-DNA complex (a 1:1 ratio) of an absorption band at 1185 cm^{-1} . This is a specific marker for the A conformation of DNA since neither the B- or C- form of DNA produce an infra-red band at 1185 cm^{-1} (Phole and Fritzsche, 1980). Hydration effects do not influence or affect the analysis of the 1185 cm^{-1} band. FTIR results show that, although dehydration can cause DNA to change conformation from B- to A-like, SASP promote this conformation change such that it reaches completion with significantly less reduction in humidity than is required for the process with DNA alone (Mohr *et al*, 1991).

(b) Also, SASP bound to DNA will protect DNA from degradation by DNase (Setlow *et al.*, 1992). Two assays are possible to show that SASP bound to DNA *in vitro* protects a nucleic acid from nuclease digestion. The first, an electrophoretic assay, is the most straightforward. Briefly, nucleic acid (including pUC19 and pUB110) is incubated with various amounts of SASP for 1 hour at 37°C . At this point DNase I (or *S. aureus* nuclease) is added and incubation carried out for a further 15 min before adding SDS/EDTA followed by NaCl and ethanol to precipitate the DNA. The precipitated DNA is analysed by agarose (2%) (for

- 7 -

polynucleotides) or acrylamide (oligonucleotides) gel electrophoresis. Protection of both pUC19 and pUB110 is evident at a ratio of SASP to DNA of 1:1 and is maximal at a ratio of 4:1. Analysis of DNase protection for four other α/β -type SASP indicate that these proteins also confer DNase resistance to this plasmid. SASP-I from *Bacillus cereus* and SASP-A show similar patterns of protected bands whereas SASP- α and - β from *Clostridia bifermentans* give different patterns (Setlow et al., 1992). The second assay is an acid precipitation assay.

(c) SASP bound to DNA protects the DNA against cleavage by restriction enzymes, particularly those with specificity for GC-rich sequences (Setlow et al., 1992). Restriction enzyme digestions of pUC19 DNA bound by SspC (8:1 ratio of SspC to DNA) were carried out and digests analysed by agarose gel electrophoresis. For enzymes rich in AT sequence i.e. *DarI* (TTTAAA) inhibition was <10%. Increasing levels of GC content in the restriction enzyme recognition site led to increased protection by SASP with those enzymes recognizing GC-rich sequences (i.e. *KpnI* GGTACC) being inhibited >75%.

(d) Also SASP increase negative superhelical density of plasmids in the presence of topoisomerase I. The method for assaying this effect is given in Nicholson et al., 1990b. In summary, 1 μ g samples of plasmid (pUC19 or pUB110) are incubated overnight in a 20 μ l volume reaction mixture at 4°C with various amounts of SspC, followed by topoisomerase I addition and further incubation for 2 h at 37°C. After deproteinization, samples are analysed by

- 8 -

electrophoresis on agarose gels containing chloroquine (2 μ g per ml). The average value of negative supertwists can be determined by comparing the position of the bands on the agarose gel with a set of standards prepared by incubating plasmid DNA with topoisomerase in the presence of differing amounts of ethidium bromide (Nicholas and Setlow, 1990). Maximum SspC binding results in introduction of a large number of negative supertwists in both plasmids. With 12 μ g SspC added to the plasmid DNA approximately 18 and 38 supercoils are introduced in pUC19 and pUB110, respectively. Since pUC19 is approximately 60% the size of pUB110, the superhelical density induced in both plasmids by SspC binding is similar. Note that the binding of protein HU to DNA which does not induce a B-to-A conformation change in DNA only induces ~40% the number of negative supertwists per unit of DNA as does SspC (Nicholson *et al.*, 1990).

(e) Also, SASP bound to DNA protects against the formation of cyclobutane-type thymine dimers upon UV irradiation, but promotes formation of spore photoproduct, an adduct between adjacent thymine residues (Nicholson *et al.*, 1991). Yields of pyrimidine dimers and spore photoproduct (SP) were <0.2% and 8% of total thymine, respectively when DNA saturated with SASP was irradiated at 254 nm with 30kJ/m². In the absence of SASP the yields were reversed - 4.5% and 0.3%, respectively (Nicholson *et al.*, 1991). Yields of SP *in vivo* i.e. in spores and thymine dimers in vegetative cells are similar and extremely high (>25% of total thymine) (Donnellan and Setlow, 1965). UV irradiation of DNA *in vitro* also ordinarily produces fluorescent bipyrimidine

- 9 -

adducts, cyclobutane type cytosine dimers and also cyclobutane dimers between cytosine and thymine as well as a 6-4 bipyrimidine adduct. The yields of all types of photoproduct are greatly reduced upon irradiation, *in vitro*, of DNA bound by α/β -type SASP (Fairhead and Setlow, 1991).

(f) It has also been demonstrated that α/β type SASP reduce the rate of depurination of DNA *in vitro* at least 20-fold. Three different procedures for measuring DNA depurination *in vitro* are given in Fairhead *et al.*, 1993.

In a further aspect, the present invention provides a polynucleotide encoding a polypeptide as defined above, for use as a medicament.

In this aspect of the invention, whilst the polypeptide is thought to be the active species, delivery of the polynucleotide to target cells for expression therein may result in expressed polypeptide inhibiting or preventing growth of the cell.

The polynucleotide may be DNA or RNA, depending on the delivery system used. Whilst it is preferred for reasons of stability and ease of manipulation that the polynucleotide is DNA, if RNA is used it eliminates the possibility of SASP inhibiting its own production. In a particularly preferred embodiment, the DNA comprises the *sspC* gene from *B. subtilis*. Degeneracy of the genetic code allows mutations which do not alter the amino acid sequence of the expression production of the DNA.

- 10 -

The polynucleotide may be used for the preparation of a medicament for inhibiting or preventing cell growth in a number of ways. In one embodiment, the medicament comprises the polynucleotide, typically formulated for administration to a subject. In another embodiment, the polynucleotide is used to manufacture a medicament comprising the polypeptide. In a further embodiment, the medicament may be manufactured inside the target cell as the polypeptide.

Without wishing to be bound by theory, it is postulated that the polypeptide, when present in the target cell binds to the DNA of the cell and prevents replication of that DNA. The polypeptide may also completely or partially inhibit or prevent transcription of the DNA with which it is associated. In this way, further cell growth is inhibited or prevented. Particularly in the case of microbial cell infection, prevention or inhibition of growth allows the subject's immune system opportunity to deal with the infected cells. Another aspect is that binding of SASP to DNA could prevent cells from expressing genes involved in evasion of host immune systems.

In a further aspect, the present invention provides a composition for inhibiting or preventing cell growth comprising a polypeptide as defined above and a delivery system therefor. In a further aspect, the present invention provides a composition for inhibiting or preventing cell growth comprising a polynucleotide as

- 11 -

defined above and a delivery system therefor which is capable of targeting a cell.

The compositions according to the present invention can be used for both medicinal and non-medicinal purposes. Where they are used for medicinal purposes such as discussed herein, there is a need to ensure that the delivery system used is suitable to treat the relevant medical condition. It is preferred to use the polynucleotide-containing composition because this can be delivered to target cells by delivery systems which are based on polynucleotides such as viruses. Where the delivery system comprises a virus, the polynucleotide may be incorporated in the genome of the virus and may therefore use the viral cell targeting mechanisms to enter the cell so that the polypeptide can be expressed in the cell to take effect. Where the target cell is a eukaryotic cell, a eukaryotic virus such as adenovirus, HSV, HIV, may be modified and used or any other virus having a specific tropism for the target cell.

In a particularly advantageous embodiment of the present invention, the virus comprises a bacteriophage (*i.e.* a bacterial virus). Bacteriophages are generally capable of targeting bacteria and are usually very specific in that any species of bacteria will have its own unique range of bacteriophages. Moreover, each bacterial strain may well have at least one bacteriophage which is unique to that strain. Thus, using a bacteriophage as a delivery system ensures that no bacteria, other than those targeted, will be infected. A list of common pathogens and some of their bacteriophages is given in appendix 4.

- 12 -

There are various types of bacteriophage, including lysogenic phages such as lambda, filamentous phages or lytic phages, which are not lysogenic. Bacteriophages can comprise single stranded DNA or RNA, to which SASP is unable to bind, as well as the more common double stranded DNA such as lambda. It is preferred to use a bacteriophage which cannot establish lysogeny, or a lysogenic phage which has been treated so that a gene involved in establishing lysogeny is inactivated. In either case it is preferred to inactivate at least one of the genes encoding products involved in the lytic process. This is advantageous because prevention of target cell lysis prevents the toxic contents of the cell being released and adversely affecting the host. One drawback of conventional antibiotics is that once the antibiotics are administered to a subject, disruption of the bacterial cell wall can be fatal to the host due to a massive immune response to cell wall components. This problem is avoided by preventing bacterial cell lysis in accordance with the present invention.

Inactivation of a lysis gene is conveniently achieved by inserting into the gene the polynucleotide according to the present invention. This can have a further advantage in that expression of lysis genes occurs sufficiently late in the life cycle of the phage that many phage particles can be produced in a host cell before the polypeptide is expressed by the polynucleotide.

- 13 -

Typical lysis genes include the *S* gene of the bacteriophage lambda. This gene encodes a holin, which is a protein which forms pores in the host cell which then allows other lytic enzymes produced by the bacteriophage to cause lysis. A polynucleotide of the present invention may be inserted within, or largely replace the *S* gene and preferably comes under control of the *S* gene promoter P_R' . Analogously, the polynucleotide may be inserted in one of the other genes involved in the lytic cycle such as the *R* gene. The *R* gene product is a lytic transglycosylase. In this case, the *S* gene may or may not be additionally disrupted. Equivalent genes in other types of bacteriophage can be used in an analogous way as locations for the polynucleotide when targeting bacteria other than *E. coli*.

In a further embodiment, the polynucleotide can be located elsewhere on the bacteriophage chromosome and placed under control of a bacteriophage or bacterial promoter. Optionally, production of one or more proteins involved in lysis could still be inhibited. Alternatively, the lytic cycle could be left to run its course. For example, it is possible to use bacterial promoters which react to cues found in a host under infection conditions such as temperature sensitive promoters, the *P3* promoter of the *Staphylococcus aureus agr* locus, or other promoters involved in two component sensor regulator pathways. Further examples include promoters active under microaerophilic conditions, under low iron conditions or those stimulated by host specific factors such as nicotinic acid or magnesium ions.

- 14 -

In a further aspect, the virus may be modified to increase or alter its host specificity. In the case of bacteriophages, these may be engineered to infect cell types other than bacteria by modifying the tail to generate different affinities and/or ability to infect cells. For example, it has been shown that mammalian cell tropism can be conferred on filamentous bacteriophage by presenting a ligand that binds to a mammalian cell surface molecule on the coat protein of the bacteriophage (Larocca *et al* 1998). For example, it has been demonstrated that when a phage M13) is engineered to display genetically the growth factor ligand, FGF2 (as a fusion to its minor coat protein pIII), it acquires the ability to deliver a gene to mammalian cells through the FGF receptor resulting in transduced cells (Larocca *et al.*, 1999). Other workers have also reported similar findings using phage that display a single chain antibody (scFvc) directed against ErbB2, a member of the EGF (epidermal growth factor) receptor family (Poul and Marks, 1999). Selection of phage engineered for receptor-mediated gene transfer to mammalian cells can be enhanced by screening phage libraries for functional ligands capable of delivering DNA to cells (Kassner *et al.*, 1999).

A barrier to Caudovirales (tailed bacteriophages) infecting cells other than their natural host is the lack of an appropriate receptor present on the surface of the target bacterium to which the phage can adsorb. By addressing this it is possible to create phages which contain the same modified DNA (*i.e.* SASP containing) but which can target broad host ranges. For example, a phage may be modified to allow it to target a receptor which is common in several

- 15 -

species of bacteria. Alternatively, the modified phage DNA may be packaged into identical phage heads which have been given a variety of tails each expressing an affinity for receptors expressed by different bacteria. Bacteriophages can also express antibody fragments as fusion proteins. For example the filamentous phage M13 has been engineered to express a g3p-fusion protein comprising a *Helicobacter pylori*-antigen-binding single-chain variable fragment (ScFv) (Cao et al., 2000). This ScFv-phage decreased the cfu of all tested strains of *H. pylori*. It may also be possible to cause a target bacterium to express a chosen receptor. For example, it has already been shown that *Pseudomonas* species can be modified to express LamB receptors, which are the receptor for lambda bacteriophage (de Vries et al., 1984). The gene, *lamB*, encoding these protein receptors is introduced into *Pseudomonas* by means of a plasmid and inserts into the *Pseudomonas* chromosome by homologous recombination. Whilst it is not always practicable to transform cells with plasmids it is possible to deliver the *lamB* gene to any Gram negative bacteria by means of a modified lysogenic bacteriophage specific to the target. The *lamB* gene should be under the control of a strong bacterial promoter and the phage should be altered so that lysogeny is always established. Administration of this type of phage, then, will render *Pseudomonas* species liable to infection by subsequently administered SASP/lambda. Other such modified phages can be produced for each target species and will act to broaden the host range of any given bacteriophage containing SASP.

In these ways, it is possible to extend the range of bacteria that a SASP containing phage can target, at least

- 16 -

within the broad categories of Gram positive or Gram negative bacteria.

Modified bacteriophage are commercially available which have been designed specifically with cloning or gene expression in mind and may comprise multiple cloning sites and inducible promoters inserted into non-essential regions.

There are two classes of lambda cloning vectors: insertion vectors accept 0-12 kb DNA and include Lambda ZAPII, Uni-ZAP XR, and Lambda ZAP-Express (Stratagene); replacement vectors accept 9-23 kb and include Lambda FIXII and Lambda DASHII (Stratagene). Bacterial protein expression kits allowing expression of toxic genes are also available including the Lambda CE6 bacteriophage carrying the T7 RNA polymerase gene for delivery to *E.coli* strain BL21 cells (Stratagene). Bacteriophages with natural mutations within the *S* gene are used commercially to manufacture large quantities.

When used as a medicament, the polypeptide or polynucleotide of the present invention may be used for human therapy and may treat various conditions, especially microbial infections. Amongst those microbial infections which are treatable according to the present invention are topical infections, dental caries, respiratory infections, eye infections and localised organ infections. The invention is applicable to both human and animal therapy and may, for example, be used to treat systemic or topical infections in fish. Medicaments or pharmaceutical

- 17 -

compositions may therefore be formulated according to the invention depending upon the use to which the polypeptide or polynucleotide is put. Typically, a medicament may be formulated which comprises the active ingredient optionally together with a pharmaceutically-acceptable excipient, diluent or carrier. The exact nature and quantities of the components of such pharmaceutical compositions may be determined empirically and will depend in part upon the route of administration of the composition. Routes of administration to recipients include oral, buccal, sublingual, by inhalation, topical (including ophthalmic), rectal, vaginal, nasal and parenteral (including intravenous, intra-arterial, intra-muscular, subcutaneous and intra-articular) For convenience of use, dosages according to the present invention will depend on the site and type of infection to be treated or prevented. For example, treatment of respiratory infections would be effected by a SASP/phage suspension administered by inhalation. Treatment of eye infections would be effected by use of a SASP/phage suspension administered by eye drops and so on. A mouthwash or toothpaste may be used in the treatment of dental caries which contains a SASP/phage formulation to eliminate bacteria associated with dental plaque formation. Accordingly, oral hygiene products containing polypeptide or polynucleotide according to the present invention are also provided.

The polypeptide, polynucleotide and compositions thereof according to the present invention may be used in non-medical applications as well. In a further aspect there is provided use of a polypeptide or polynucleotide as defined

- 18 -

herein as a microbial decontaminant, more particularly a bacterial decontaminant which may be used to treat surface microbial contamination, may be used in land remediation or in water treatment. For example, the polynucleotide or polypeptide may be used in the treatment of medical personnel as a decontaminating agent, for example as a hand wash. Treatment of work surfaces and equipment is also provided, especially that used in hospital procedures or in food preparation. This has an advantage over conventional antibacterial chemicals which can damage delicate instruments and may be undesirable in food preparation areas. As a further example of surface microbial decontamination, the invention may be used in the topical treatment of carcasses. In the treatment of water, the present invention may be effective against water borne pathogens, especially *Vibrio cholerae*, *Legionella pneumophila*, *Salmonella typhi* and *Shigella dysenteriae*. Microbial contamination of land may equally be combated according to the present invention.

In a further aspect, there is provided use of the polypeptide or polynucleotide as an antimicrobial agent, particularly an antibacterial or antifungal agent, in the treatment of plant material such as plants, for example crops, or in the treatment of seeds or grain produced therefrom. Fruits may be sprayed with phages against bacteria causing soft rots. Microorganisms such as *Erwinia* species may be treated in this way. Ornamental plants such as geraniums are susceptible to bacterial blight caused, for example, by *Xanthomonas campestris*; this organism also affects tomatoes. Similarly *Pseudomonas* species which

- 19 -

infect beans and mushrooms can also be treated according to the present invention.

In a further aspect, the polynucleotide or polypeptide may be used to treat vermin such as rats so as to eliminate specific bacteria therefrom. A common treatment to eliminate rats is the administration of feed containing anticoagulant substances such as warfarin. The antidote to such substances is commonly vitamin K. Vitamin K is produced in the mammalian gut by bacteria. Resistance to anticoagulants by rats is acquired due to colonisation of the gut by bacteria which produce elevated levels of vitamin K. Therefore the treatment of vermin according to the present invention allows conventional anticoagulant administration to be successful in vermin control.

The invention will now be described in further detail, by way of example only, with reference to the accompanying drawings and the following examples and appendices.

Brief Description of the Drawings

FIGURE 1 shows a diagrammatic representation of part of the lambda genome, spanning the *S* gene;

FIGURE 2 shows a map of pB/LF1;

FIGURE 3 shows a diagrammatic representation of part of the *Bacillus subtilis* genome spanning the *sspC* gene;

FIGURE 4 shows a map of (A) pB/SAPB and (B) pB/SAPO;

FIGURE 5 shows a map of pB/SAPOC;

FIGURE 6 shows a map of SSPC-lambda showing the substitution of the lambda *S* gene by the *sspC* gene from *B.*

- 20 -

subtilis and insertion of a chloramphenicol resistance marker gene (Cm^r);

FIGURE 7 shows a map of an area of SSPC-lambda genomic DNA with primer positions;

FIGURE 8 shows a diagrammatic representation of part of the *Bacillus subtilis* genome spanning the *sspC* gene;

FIGURE 9 shows a map of pB/PIPC;

FIGURE 10 shows a diagrammatic representation of a fragment comprising the RPPC-lambda construct, showing position of sequencing primers SEQL1F and SEQL2R;

FIGURE 11 shows a diagrammatic representation of tandem *sspC* genes and the primers used to PCR amplify the genes prior to ligation into lambda;

FIGURE 12 shows the decrease in viability of *E. coli* following infection with SSPC-lambda; and

FIGURE 13 shows a gel demonstrating the banding patterns of plasmid DNA prepared from strains grown +/-production of SspC.

EXPERIMENTAL PROCEDURES

All experimental procedures are standard as described in Sambrook et al. (1991) unless stated otherwise.

Restriction digestions were carried out in a total volume of 50 µl, using 2 µl of each enzyme, and incubated at 37°C for 4 h, unless otherwise stated.

Dephosphorylation of template DNA was carried out in a total volume of 50 µl using 10X buffer (5 µl) and alkaline phosphatase (2.5U) (5 µl) with incubation at 37°C for 1 h.

- 21 -

Ligations were carried out in a total volume of 10 μ l using 3 Weiss Units (1 μ l) of T4 DNA ligase and were routinely performed at 16°C overnight.

PCR mixes were routinely made up as follows (total volume of 100 μ l):

Template DNA	0.1 μ g plasmid or purified lambda DNA/1 μ g chromosomal DNA/1 colony
10X Buffer (with 1.5 mM MgCl ₂)	10 μ l
dNTP mix (10 mM stock)	2 μ l
Taq Polymerase (2.5U)	1 μ l
Primers (Forward and Reverse)	100 pmoles of each
Adjust to a final volume of	100 μ l with dH ₂ O

PCR reactions were carried out as follows: (unless otherwise stated)

95°C for 3 mins (denature)	
94°C for 30 sec (denature)	)
58°C for 30 sec (anneal)	) for 25 cycles
72°C for 30 sec per kb of DNA (extend)	)
72°C for 10 mins	

Primers were obtained from Gibco BRL or Sigma Genosys. Where primers include recognition sequences for restriction

- 22 -

enzymes, the preferred upstream sequence of each enzyme (PCR Essential Data, 1995) was included.

A *In vitro/in vivo* production I

1. A fragment of the lambda genome, spanning the *S* gene, was amplified by PCR using primers with suitable restriction enzyme sites at the 5' end to allow directional ligation into a general *E. coli* cloning vector such as pUC18 or pBluescript (Stratagene). Thus, Primer B1 comprises the restriction enzyme recognition sequence of ***Pst*I** followed by sequence of lambda from base 44660 to base 44677 (Figure 1). Primer B2 includes the restriction enzyme recognition sequence of ***Xba*I** followed by the reverse and complement of lambda sequence from base 45972 to base 45956 (Figure 1), for example:

Primer B1: 5'-AACTGCAGGGTCACTTCGACGTATCG-3' (SEQ ID NO:2)

Primer B2: 5'-GCTCTAGAGCTCATAATCAATCTC-3' (SEQ ID NO:3)

In Figure 1, the position of the late genes involved in lysis, together with the P_R promoter are shown relative to each other. The position of primers B1 and B2, together with the *Eco*RI restriction enzyme site, are also shown.

2. The resulting 1328 bp PCR product was digested with *Pst*I/*Xba*I and ligated with similarly digested, dephosphorylated pBluescript to give pB/LF1 (Figure 2). Figure 2 shows a linear map of pB/LF1 showing the plasmid backbone of pBluescript SK (+) (Stratagene) and the

- 23 -

position of the lambda fragment insert bordered by *Pst*I/*Xba*I restriction sites (see Figure 1). The sequence spanning the start of the *S* ORF is given together with the position of the ribosome binding site (rbs), and the first and second start codons. The relative positions and sequences of the inverse PCR primers are shown. Primer B3 produces a PCR product which is blunt ended at the 5' end. Primer B4 produces a PCR product which, following digestion with *Nco*I, has a 5' end overhang.

3. Plasmid pB/LF1 was introduced into *E. coli* by electroporation and putative recombinants were recovered as white colonies on LB agar plates in the presence of X-gal (80 µl, 20 mg/ml) and ampicillin (50 µg/ml). A correct transformant was identified following restriction digestion of the plasmids with *Eco*RI, resulting in two fragments of approximately 300 bp and 3950 bp.

4. The *S* gene of lambda is a dual start gene, with transcription from the second fMet start codon resulting in a 2-fold greater level of protein. Therefore, the chosen SASP gene, in this instance *sspC* from *B. subtilis*, was inserted in frame with this second start codon. Inverse PCR of plasmid pB/LF1 was carried out (with an extension time of 4 min 30 sec at 68°C) using reverse primers to produce a fragment with a 5' end overhang. The restriction enzyme *Nco*I has a recognition sequence (CCATGG) which incorporates the nucleotides ATG. By adding the *Nco*I recognition sequence to the front of template (pB/LF1) and insert (*sspC*) DNA primers it allows subsequent ligation of

- 24 -

these PCR products so that the *sspC* gene is in frame with the start codon of the lambda *S* gene.

The reverse primer (B4) is the complement of lambda sequence starting at the third nucleotide 5' of the second ATG start codon of the *S* gene (Figure 2). The primer contains the recognition sequence of the restriction enzyme **NcoI**, for example:

Primer B4: 5'-CATG**CCATGGT**CATGTCTTACC-3' (SEQ ID NO: 4)

It is possible to replace the *S* gene with a SASP gene by blunt end ligation and in this case a reverse primer which begins at the complement of the second ATG start codon of the *S* gene (Figure 2) can be used, for example:

Primer B3: 5'-CATCTTCATGTCTTACC-3' (SEQ ID NO:5)

The forward primer was based on sequence at the beginning of the lambda *R* gene from base 45499 to base 45515 (see Figure 2). The recognition sequence for restriction enzyme **SpeI** was used in front of the lambda sequence to allow directional ligation with the *sspC* gene, for example:

Primer B5: 5'-GG**ACTAGT**GAAATCAATAATCAACG-3' (SEQ ID NO:6)

5. The *sspC* gene was PCR amplified (using 20 sec extension time) in such a way as to enable ligation to either of the inverse PCR products obtained from primers B3 and B5, or B4 and B5, for example:

- 25 -

(i) to ligate to the pB/LF1 inverse PCR product produced using primers B3 and B5 (to give plasmid pB/SAPB), a forward primer should be used which begins with the nucleotide immediately 3' of the ATG start codon of the *sspC* gene (Figure 3), for example:

Primer B6: 5'-GCTCAACAAAGTAGATCAAG-3' (SEQ ID NO:7)

(ii) to ligate to the pB/LF1 inverse PCR product produced using primers B4 and B5 (to give plasmid pB/SAPO), a forward primer comprising the sequence of *sspC* starting at the 5th nucleotide of the *sspC* ORF was used (Figure 3). This primer has an **NcoI** restriction enzyme sequence immediately prior to the *sspC* sequence, which in fact incorporates the first four nucleotides of the *sspC* gene itself, for example:

Primer B7: 5'-CATG**CCATGG**CTCAACAAAGTAGATCAAG-3' (SEQ ID NO:8)

The reverse primer is the complement of sequence at the end of the *sspC* ORF, i.e. to produce a PCR product which includes the stop codon of the *sspC* gene (Figure 3). The primer includes **SpeI** sequence to allow directional ligation with either inverse PCR product of pB/LF1, for example:

Primer B8: 5'-GG**ACTAGT**TTAATGAAATTGACCG-3' (SEQ ID NO:9)

In Figure 3, *sspC* gene is shown together with the relative positions of the PCR primers, B6, B7 and B8. Primer B6 will produce a PCR product with is blunt ended

- 26 -

at the 5' end. Primer B7 produces a PCR product which, following digestion with *NcoI*, will have a 5' overhang.

6. The PCR amplified *sspC* gene (from primers B7 and B8) and inverse PCR amplified pB/LF1 (from primers B4 and B5) were digested with the restriction enzymes *NcoI* and *SpeI*. Digested linear pB/LF1 inverse PCR product was dephosphorylated prior to ligation.

7. After cleaning of digested DNA, ligations were carried out to give plasmid pB/SAPO in which the *sspC* gene largely replaces the *S* gene of lambda (Figure 4). For plasmid pB/SAPB PCR products are simply ligated together (Figure 4). Figure 4 shows a linear map of (A) pB/SAPB or (b) pB/SAPO. These plasmids are constructed following insertion of the *sspC* gene into inverse PCR amplified plasmid pB/LF1 (amplified using primers B3 and B5 or B4 and B5 (see section A 4)).

(A) Linear map of pB/SAPB showing inverse PCR amplified pB/LF1 (from primers B3 and B5) containing the *sspC* gene. The sequence given spans the *S* gene ribosome binding site and start of the *sspC* ORF, joined by blunt end ligation. Linear map of pB/SAPO showing inverse PCR amplified pB/LF1 (from primers B4 and B5) containing the *sspC* gene. The sequence given spans the *S* gene ribosome binding site and start of the *sspC* ORF, joined by ligation following digestion with *NcoI*.

8. It is possible to produce a lambda carrying a SASP gene with, or without an antibiotic resistance gene present. Use of an antibiotic resistance gene provides a

- 27 -

selectable marker to track the presence of a SASP gene and this has been carried out using a chloramphenicol resistance (Cm^r) gene. A Cm^r gene (with its own promoter) has been inserted, in the opposite orientation, at the 3' end of the *sspC* gene following digestion of pB/SAPO with *SpeI*. This resulted in plasmid pB/SAPOC (Figure 5). Figure 5 shows a linear map of pB/SAPOC showing pBluescript backbone and the position of the *sspC* and Cm^r genes within the lambda fragment bordered by *PstI/XbaI* restriction sites.

9. One method of producing SASP/lambda is to infect a strain of *E. coli* carrying pB/SAPOC with phage lambda. As the phages reproduce, the lambda/*sspC*/ Cm^r fragment within pB/SAPOC will become incorporated into some lambda genomes. This method has successfully been employed using a temperature sensitive (ts) lambda. This type of lambda can be stably maintained, as a prophage, within an *E. coli* chromosome at 30 °C but not at 42 °C. The pB/SAPOC-bearing strain was grown in LB (containing 10 mM MgSO_4 + 0.2% maltose (w/v)) until the OD_{600} reached 0.3. An aliquot (100 μl) was removed and mixed with 100 μl of lambda phage preparation. The mix was incubated without shaking at RT for 20 min, 3.5 ml molten top agar (LB 0.6% agar containing 10 mM MgSO_4 + 0.2% maltose (w/v)) held at 45 °C, was added and poured onto pre-warmed LB agar plates. Plates were incubated overnight at 37 °C before LB (3 ml) was added onto the surface of the top agar. The top agar containing the plaques was transferred into 50 ml centrifuge tubes and stored at 4 °C overnight. Chloroform (250 μl) was added and the tube was gently inverted several times to lyse any whole bacterial cells, prior to centrifugation (4,000 rpm,

- 28 -

10 min, RT). The resulting phage lysate supernatant was transferred to a sterile tube and used to infect a strain of *E. coli* which could be lysogenised i.e. NM522 or Y1089r⁻, by mixing 100 µl lysate with 100 µl *E. coli* culture grown to an OD₆₀₀ of 0.3. Following incubation at RT for 30 min, 800 µl LB was added and the mix was plated out in 100 µl aliquots onto LB agar plates supplemented with chloramphenicol (10 µg/ml). Following incubation at 30 °C overnight Cm^r colonies were isolated and examined for the presence of *sspC*-carrying lambda prophages.

10. Cm resistant colonies were sub-cultured onto two LB plates containing chloramphenicol (10 µg/ml) and the plates were incubated at either 30 °C or 42 °C overnight. Colonies which had grown the following day at 30 °C but not at 42 °C were assumed to be lysogenic for recombinant lambda containing the *sspC* and Cm^r genes. Colonies were also sub-cultured onto LB plates containing ampicillin to ensure that the whole pB/SAPOC plasmid had not integrated into the lambda genome. A strain of *E. coli* which was lysogenic, Cm resistant and ampicillin sensitive was identified and the prophage designated SSPC-lambda (Figure 6). Figure 6 shows a linear map of SSPC-lambda showing the substitution of the lambda *S* gene by the *sspC* gene from *B. subtilis* and insertion of a chloramphenicol resistance marker gene (Cm^r).

11. Sequencing reactions were carried out to confirm the presence, fidelity and orientation of the *sspC* and Cm^r genes within the SSPC-lambda genome present in the host *E. coli* chromosome. Chromosomal DNA was prepared from the *E.*

- 29 -

coli strain containing SSPC-lambda and digested with the restriction enzyme *Cla*I. This enzyme cuts at 15 sites within the lambda genome and an undetermined number of sites within the *E. coli* genome. Specifically, this enzyme cuts at bases 43825 and 46439 of the lambda genome, resulting in a fragment which spans the *S* and *R* lysis gene area of lambda bordered by primers B1 and B2 (Figure 7). Figure 7 shows an area of SSPC-lambda genomic DNA with primer positions:

- position of primers B1 and B2 used to initially amplify lambda fragment to make pB/LF1 (section A 1)
- position of *Cla*I sites showing extent of ligation product for PCR amplification and sequence verification (section A 11)
- primers B31 and B32 used to PCR amplify region of lambda spanning B1-B2 fragment, for sequencing (section A 11)
- primers 13f1, B30, B55 and B54 used for sequencing SSPC-lambda construct (section A 11).

Total digested DNA was then ligated overnight and an aliquot of the ligation mix (2.5 µl) was used as template DNA for a PCR reaction using the following programme:

95 °C for 3 mins (denature)

94 °C for 20 sec (denature))

62 °C for 30 sec (anneal)) for 10 cycles

68 °C for 3 min 50 sec (extend))

- 30 -

94 °C for 20 sec (denature))
62 °C for 30 sec (anneal)) for 25 cycles
68 °C for 3 min 50 sec + 10 sec)
extension time (extend)

72 °C for 10 mins

The following primers (B31 from base 43976 to 44000; B32 from base 46225 to 46203 of lambda) were used to produce a fragment of lambda DNA spanning the lambda/*sspC*/Cm^r gene DNA which had originated from pB/SAPOC as a *Pst*I/*Xba*I insert (Figure 7).

Primer B31: 5'-GGTACTGATGTGATGGCTGCTATGG-3' (SEQ ID NO:10)

Pimer B32: 5'-GCAACATCATCACGCAGAGCATC-3' (SEQ ID NO:11)

The resulting PCR product was then used in several sequencing reactions using the following primers (see Figure 7):

Primer B30 5'-CAACAGTACTGCGATGAGTGG-3' (SEQ ID NO:12)

Primer 13f1 5'-GTAGTGAGATGAAAAGAG-3' (SEQ ID NO:13)

Primer B54 5'-GTAGGTAATGGCGTTATCACG-3' (SEQ ID NO:14)

Primer B55 5'-GGTGGTGCGTAACGGCAAAAGC-3' (SEQ ID NO:15)

- 31 -

12. It is also possible to produce a similar construct using a different ribosome binding site (rbs) upstream of the SASP gene as an alternative to the native S gene rbs. For example, the T7 phage gene 10 leader RNA can dramatically enhance the expression of some foreign genes in *E. coli* (Olins et al., 1988). Alternatively, the ribosome binding site sequence of the lambda V gene could be used as V encodes tail protein which is more abundant than the S gene product during the normal lytic life cycle of the bacteriophage lambda. In this instance, a construct has been produced using the native *sspC* rbs employing the same method as above, except the *sspC* gene was PCR amplified using a forward primer homologous to sequence approximately 40 bases upstream of the *sspC* start codon. A **BamHI** restriction enzyme site was included in front of the *sspC* sequence. For example:

Primer B23: 5'-CG**GGATCC**GATTCAAACAAGCTTG-3' (SEQ ID NO:16)

Reverse primer B8 was used. The resulting PCR product was ligated with an inverse PCR amplified pB/LF1, amplified using forward primer B5, as previously, and a reverse primer, B21 with a **BamHI** restriction site in front of the pB/LF1 sequence:

Primer B21: 5'-CG**GGATCCC**ATCTTCATGTCTTTAC-3' (SEQ ID NO:17)

Production and identification of a strain carrying this form of lambda, designated SPPC-lambda, as a prophage was

- 32 -

carried out as for SSPC-lambda. SPPC-lambda was also sequenced as described in section A 11 above.

13. Both SSPC- and SPPC-lambda constructs are maintained as prophages, that is they remain stably within their host *E. coli* chromosome. Only first generation mature phage particles have so far been used for infection. This helps to ensure comparability between each batch of mature phage produced. However, since it is not necessarily ideal to use a temperate, or lysogenising, phage for therapeutic purposes it is possible to alter the genes involved in establishing lysogeny so that they are inactive in an infective situation. In the system described here, the use of a temperature sensitive (ts) phage, means that lysogenisation is relatively rare at 37 °C or above. Of course, phage stocks themselves can also be maintained rather than lysogenic *E. coli*.

14. Preparations of both SSPC-lambda and SPPC-lambda were obtained by inducing the recombinant prophage-carrying strains to produce mature phage particles. Each strain was grown at 30 °C until the OD₆₀₀ reached 0.6 and then the temperature was shifted to 42 °C for 15 minutes. The culture was then incubated at 37 °C, with shaking at 350 rpm to provide good aeration, for a further 3 h prior to harvesting by centrifugation (4,000 rpm, 10 min, RT). The supernatant was removed and the pellet resuspended in 1/5th volume of phage buffer. Chloroform (1/100th volume) was added to the resuspended cells and the suspension was mixed gently. The resultant lysate was centrifuged (4,000 rpm, 10 min, RT) and the supernatant transferred to a sterile tube

- 33 -

and then stored at 4 °C. The lysates were titred as described in section A 15, below.

15. To titre SSPC-lambda phage particles produced following induction, phage lysate was used to infect a non-lysogenising strain of *E. coli* containing a plasmid (designated pB/LF2) carrying a fragment of lambda DNA spanning the *S* and *R* lysis genes and $P_{R'}$ promoter. This promoter-containing fragment of lambda was PCR amplified using primer B51 (5'-AACTGCAGCGCTGTGACGATGCTAATCC-3' SEQ ID NO:18) from base 44371 to base 44390 and primer B2 (previously described) (see Figure 7). The presence of reproducing lambda phages within the pB/LF2-bearing strain allows expression of the lysis gene cassette downstream from the plasmid based $P_{R'}$ promoter. The lysis genes' products expressed from the plasmid facilitate lysis of the bacteria and the formation of plaques. Phage titre is determined by plaque enumeration at the dilution where plaques are discrete and easily observable. Infection was carried out by growing the strain containing pB/LF2 to an OD₆₀₀ of 0.3 in LB containing 0.2% maltose, 10 mM MgSO₄ and 50 µg/ml ampicillin. An aliquot (100 µl) of the cell culture was incubated with 100 µl of dilutions of SSPC phage lysate for 20 min at RT and then mixed with top agar and plated out as described in section A 9. There is up to a 5-log reduction in the titre of SSPC-lambda particles, compared to the parental lambda from which it is derived. Following the described protocol the parental lambda can produce approximately 10¹⁵ pfu per ml.

- 34 -

B *In vitro/in vivo* production II

There are alternative methods for obtaining lambda containing a SASP gene in place of the lambda *S* gene, based on transforming a lambda lysogen with pB/SAP0 or pB/SAPB (see section A above). In this case, competent cells should be prepared of a restriction⁻/modification⁺ strain of *E. coli* which is a lambda lysogen, for example MOB145.

1. Electro-competent lysogenic *E. coli* cells should be transformed with either pB/SAP0 or pB/SAPB, or a suicide vector containing the equivalent lambda/*sspC* fragment of DNA. The transformed cells are allowed to recover for 1 h in SOC at 37 °C then centrifuged (4000 rpm, 10 min, RT). The pelleted cells should be resuspended in LB (1 ml) and 50 µl removed and made up to 1 ml with sterile LB. Cells should be plated out onto LB agar in 200 µl aliquots and incubated overnight at 37 °C. The remaining 950 µl should be flash frozen in 50 µl aliquots and stored at -20 °C.

2. There are several ways in which to select for double cross-over event between the lambda fragment carried in the pB/SAPB or pB/SAP0 plasmids and homologous sequence within the lambda genome. The use of a suicide vector can encourage double cross-over event since the vector cannot be maintained within the *E. coli* lysogen. Colonies of strains carrying potentially recombinant lambda prophages obtained from overnight growth on LB agar plates (see section A 9 above) can be PCR screened using primers which are based in the *sspC* gene and lambda, i.e. B1 and B8 or B2 and B7 (see section A). The resulting PCR product using

- 35 -

either primer pair should be approximately 1.3 kb. Alternatively, a method based on induction of the lambda prophage can be employed since SASP-containing phage will no longer have a functional *S* gene and will not be able to lyse their host cells. Screening can be carried out by either:

i) UV irradiation of transformed cells according to Hendrix *et al.* (1983). Resuspend an aliquot of cells (20 μ l) from above (step 9) to a maximum cell suspension of 2×10^8 cfu in 10 ml of a suitable non UV absorbing suspension medium (e.g. M9a or PBS) in a standard petri dish (9 cm). Irradiate cells using a UV light source (maximum output 260 nm). Following irradiation, induced cultures are incubated in M9a medium at 37°C with aeration (if PBS is used as the suspension medium, fresh sterile growth medium (1/10th volume of 10X M9a is added). Photoreactivation is prevented by protecting the irradiated bacteria from visible light.

ii) Induction of *thy*⁻ lambda lysogens by thymidine starvation, according to Hendrix *et al.* (1983). Isolate *thy* mutants (Miller, 1972): The lysogenic strain should be grown in M9a medium supplemented with 10 μ g/ml thymidine until 2×10^8 cfu/ml. Cells should be washed and resuspended in thymidine free M9a medium and then incubated at 37°C for 2 h. Thymidine (10-25 μ g/ml) should then be added to the culture and a further incubation for 90-120 min at 37°C carried out.

- 36 -

iii) Temperature shift induction (if lambda cIts lysogen is used) as described in section A.

3. Cells should be allowed to grow for ~2 hours (in the presence of 0.2% glucose to reduce numbers of any free (and therefore potentially SASP-free) phage binding to unlysed bacterial cells). Any free phage must be separated out from cells which potentially contain the SASP/bacteriophage, by centrifugation (4,000 rpm, 10 min, RT). Pelleted cells should be resuspended in LB containing 0.2% glucose and incubation continued for approximately 1 h. Cells should be centrifuged (4,000 rpm, 10 min, RT), resuspended in LB (2 ml) and then lysed with chloroform (0.02 ml). Mature phage released from cells following chloroform-induced lysis should be separated from cellular debris by centrifugation (4,000 rpm, 15 min, RT).

4. Bacteriophage containing SASP should be enriched and purified by a suitable method. One such method is to infect a growing culture of susceptible *E. coli* cells with SASP-lambda and repeat step B 3 above.

5. The presence of recombinant lambda should be verified by isolating DNA from putative SASP-lambda constructs and carrying out PCR screening to confirm the presence of the SASP gene using appropriate primer pairs, as discussed in section B 2. Putative constructs are also sequenced and titred as described in section A.

- 37 -

C *In vitro* production (I)

It is possible to produce a lambda phage carrying a SASP gene solely by *in vitro* methods. This has been accomplished by insertion of the *sspC* and Cm resistance genes within the *R* lysis gene of lambda.

1. The lambda genome was digested with *KasI*, whose recognition sequence comprises a unique restriction site in lambda, occurring at base 45679, within the peptidoglycan hydrolase encoding gene, *R*. Digested lambda DNA was then dephosphorylated.

2. The *sspC* gene was PCR amplified with an extension time of 20 sec, using:

(i) a forward primer, B13, comprising a ***PstI*** restriction enzyme sequence (with preferred upstream bases) and sequence upstream of the *sspC* ribosome binding site (Figure 8). The ribosome binding site used is that of *sspC* itself but could incorporate alternative sequence with the aim of potentially increasing translation (see section A 12).

Primer B13: 5'-AA**CTGCAG**GATTCAAACAAGCTTG-3' (SEQ ID NO:19)

ii) reverse primer B8.

3. The *sspC* PCR product was digested with *PstI* and *SpeI* and ligated to similarly digested, dephosphorylated pBluescript SK (+) to give pB/PIP. A Cm^r gene (see

- 38 -

section A 8) was inserted, in the opposite orientation, at the *SpeI* site at the 3' end of the *sspC* gene to give pB/PIPC (Figure 9). Figure 9 shows a linear map of pB/PIPC. The position of primers B26 and B27 is also shown.

4. The *sspC*/Cm fragment present in pB/PIPC was PCR amplified using:

i) a forward primer incorporating a **KasI** restriction enzyme site in front of the *sspC* ribosome binding site sequence (see Figure 9):

Primer B26: 5'-AACAGGCGCCGATTCAAACAAGCTTG-3' (SEQ ID NO:20)

ii) a reverse primer incorporating a **KasI** restriction enzyme at the end of the Cm^r gene (see Figure 9):

Primer B27: 5'-AACAGGCGCCAGTATACACTCC-3' (SEQ ID NO:21)

5. The resulting PCR product was digested with *KasI* and ligated into similarly digested, dephosphorylated lambda genome (see section C 1) to give SPPC-lambda (Figure 10).

6. The recombinant lambda DNA was packaged *in vitro* according to method of (Hohn and Murray, 1977) or using a kit such as Packagene (Promega).

- 39 -

7. Serial dilutions (down to 10^{-5}) were made of packaged lambda in phage buffer. An aliquot (100 μ l) from each packaging extract dilution was added to a vial containing 0.1 ml of *E.coli* strain NM522, freshly grown to an OD₆₀₀ of 0.3 in LB containing 10 mM MgSO₄ and 0.2% maltose (w/v).

8. The preadsorption mixture was incubated at RT for 20 minutes before the mixture was pipetted in 100 μ l aliquots onto the dried surface of an LB agar plate containing chloramphenicol (10 μ g/ml). The plates were inverted and incubated overnight at 30 °C.

9. Colonies present following overnight incubation were putative lysogens with the *R* lysis gene of lambda insertionally inactivated by the *sspC* gene. Approximately 50 colonies were transferred to two LB plates containing chloramphenicol (10 μ g/ml) and the plates were incubated overnight at either 30 °C or 42 °C. Colonies which grew at 30 but not at 42 °C in the presence of chloramphenicol were assumed to be lambda lysogens containing the *sspC* and *Cm^r* genes. An RPPC-lambda construct was isolated and sequenced as described in section A to confirm the integrity of the *sspC* and *Cm* resistance genes and that they had integrated correctly into the lambda genome. Sequencing primers, SEQL1F from base 45613 to base 45629 (5'-CTATTTACTGATTACTC-3' (SEQ ID NO:22) and SEQL2R from base 45792 to base 45776 (5'-CTTAATCTGCTGCAATG-3' (SEQ ID NO:23) were used (see Figure 10).

- 40 -

D. *In vitro/in vivo* production using tandem *sspC* genes

It has already been stated that protein-protein contacts are formed between α/β -type SASP while bound to DNA (Hayes and Setlow, 1998). It is possible that the formation of potential protein-protein binding surfaces induced by DNA could direct the further addition of α/β -type SASP molecules to the ends of DNA bound protein clusters, and therefore regulate protein binding (Hayes et al., 2000). The initial rate of binding of some (though not all) α/β -type SASP is second order with respect to initial unbound protein concentration, suggesting that two SASP monomers might be required for each productive binding event to occur (Hayes et al., 2000). In view of this it can be preferable to increase the level of SspC within the cell. Apart from regulating the level by means of a strong promoter or, as discussed in section A 12, a translational enhancer sequence and a consensus ribosome binding site with an optimized spacer region to enhance translation of SASP, two SASP genes can be inserted, in tandem, into the lambda genome. It is possible to achieve this using, in part, primers and methods given in previous sections.

For example to create tandem *sspC* genes in place of the lambda *S* gene, the *sspC* gene should be PCR amplified using primers (B6) or (B7) with a reverse primer (B15) (Figure 11):

Primer B15: 5'-GG**ACTAGTCGACGCGT**TTAATGAAATTGACCG-3'
(SEQ ID NO:24)

- 41 -

In Figure 11, the tandem *sspC* genes are shown together with the primers used to PCR amplify the genes prior to ligation into inverse PCR product of pB/LF1. The product of primers B6 or B7 and B15 are ligated into inverse PCR product of pB/LF1 amplified using primers B3 and B5 or B4 and B5 (see Figure 2). The resulting plasmids, pB/SAPB2 or pBSAPO2 respectively, are then digested with *MluI* and *SpeI* and the similarly digested PCR product of primers B16 and B8 inserted, to give either pB/SABP2T or pB/SAP02T, respectively.

Primer B15 is similar to B8 except that it incorporates a unique restriction sequence, i.e. for *MluI*, between the *sspC* sequence and the *SpeI* recognition sequence. For the second *sspC* gene, primer B8 should be used with a forward primer (B16) that comprises the same *sspC* sequence as primers B13 and B23, but incorporating a restriction site that is compatible with the *sspC* PCR product produced from primer B15 (i.e. *MluI*) (Figure 11):

Primer B16: 5'-CG**ACGCGT**GATTCAAACAAGCTTG-3' (SEQ ID NO:25)

Although the rbs sequence given is that of *sspC* itself, alternative leader sequence could be substituted to influence expression of this second *sspC* gene (see section A 12).

The PCR product resulting from amplification of *sspC* using primers B6 or B7 and B15 should be ligated with inverse PCR product of plasmid pB/LF1, amplified as described in section A. The resultant plasmid, pB/SAPB2 or pB/SAP02,

- 42 -

respectively should then be digested with *Mlu*I and *Spe*I and dephosphorylated. The PCR product resulting from amplification of *sspC* using primers B16 and B8 should be digested with *Mlu*I and *Spe*I and ligated with either of the above digested plasmids to give either plasmid pB/SAPB2T or pB/SAP02T, respectively. Again, a *Cm^r* gene can be inserted at the *Spe*I site at the end of the second *sspC* gene. Integration of this construct into lambda can be accomplished as described previously in section A.

Alternatively a different SASP gene, such as, SASP β from *Clostridium bifermentans* could be inserted after the *sspC* gene or on its own since SASP β has a greater DNA binding affinity than *sspC*, although it is less well characterised (Hayes *et al.*, 2000).

E EXAMPLES OF EFFECT OF SASP

1. An example procedure for testing the *in vitro* efficacy of SASP, delivered by a bacteriophage carrying an *sspC* gene, to cause a reduction in viability of *E. coli* cells is as follows:

i. The *E. coli* strain to be infected is grown overnight from frozen stock or fresh agar plate in λ LB (LB containing 0.2% maltose and 10 mM MgSO₄).

ii. This overnight culture is used to inoculate 3 ml λ LB (to an OD₆₀₀ of 0.02) which is then grown at 37 °C, shaking at 350 rpm until the OD₆₀₀ reaches approximately 0.3. An

- 43 -

aliquot of this culture (1 ml) is then used directly, or 100 μ l is used to make serial dilutions in 0.9 ml λ LB, as appropriate so that the ratio of phage numbers to cell numbers can be varied as required.

iii. Aliquots (1 ml) of this cell culture are then transferred to a sterile Universal tube and phage lysate, or a dilution of phage lysate (made as described previously) (1 ml) is added. The cell/phage mix is incubated at 37 °C, without shaking, for 30 min and then 2 ml fresh λ LB is added.

iv. The OD₆₀₀ of each test sample is taken and an aliquot (100 μ l) is removed, diluted in phosphate buffered saline (PBS) and 100 μ l of suitable dilutions spread onto LB plates. Incubation of the samples and control is continued at 37 °C with shaking at 250 rpm and at suitable time points, for example hourly, this step is repeated.

v. Plates are incubated overnight at 37 °C and the following day, the number of colony forming units (cfu) on each plate is determined.

2. Typical results (from 4 experiments) of infecting cells by this procedure with, for example, SSPC-lambda, are given in the following table.

- 44 -

TABLE 1: Viability of *E. coli* cells following infection with SSPC-lambda

Time (h)	OD ₆₀₀	cfu/ml
pre-infection	0.35	1.4×10^8
post-infection	0.15	1.2×10^7
1 h post-infection	0.13	5.4×10^6
2 h post-infection	0.23	1.3×10^6
3 h post-infection	0.33	7.0×10^5
4 h post-infection	0.52	5.2×10^5
5 h post-infection	0.58	3.2×10^5

E. coli cells were grown to an OD₆₀₀ of 0.35 which corresponded to approximately 1.4×10^8 cells/ml. An aliquot (1 ml) of cell culture was infected with approximately 1×10^{10} SSPC-lambda phages (1 ml of lysate containing approximately 10^{10} phage/ml), as previously described, prior to addition of 2 ml fresh LB.

From four infection experiments it has been observed that by 30 minutes post-infection of *E. coli* with SSPC-lambda there is a $\geq 60\%$ drop in cell viability compared to cell numbers pre-infection; this drop in cell viability routinely increases to $\geq 95\%$ by 3 hours post-infection. The decrease in cell viability taken from the experiment detailed in Table 1 is shown in Figure 12.

3. The foregoing data can be compared to that routinely observed following production of SspC in a strain carrying an expression plasmid containing the *sspC* gene. Such a plasmid has been constructed, (pET/PIP) with the *sspC* gene inserted into the expression vector, pET24d (Novagen). In this plasmid, *sspC* is under the control of the T7 RNA polymerase gene promoter and production of SspC is largely

- 45 -

repressed by the presence of 0.2% glucose in the growth medium and induced by the addition of IPTG (to 1 mM). Sequence data, obtained using standard primers T7 and B8, confirming the insertion of *sspC* and its integrity is given in Appendix 7. Table 2 details typical results (from 3 experiments) obtained when strain PTL14 (*E. coli* strain BL21 λ DE3 containing pET/PIP) is grown as follows:

- i) Strain PTL14 was grown in 25 ml LB containing Kanamycin (30 μ g/ml) in a 100 ml flask at 37 °C with shaking at 250 rpm to an OD₆₀₀ of 0.25. The culture was then divided, with 12.5 ml being transferred to a fresh 100 ml flask.
- ii) The culture in one of the flasks was induced by the addition of IPTG (to 1 mM) and both flasks were incubated at 37 °C with shaking at 350 rpm. Aliquots (0.5 ml) were taken from the control and sample cultures immediately pre-induction and at 30-60 min intervals thereafter for 3 hours and at 24 hours.
- iii) These aliquots were used to obtain OD₆₀₀ readings and also used to make serial dilutions as appropriate in LB, and spread in 100 μ l aliquots onto LB agar plates containing Kanamycin (30 μ g/ml). Plates were incubated overnight at 37 °C and colony forming units (cfu) on each plate were counted and used to determine cfu per ml.

These experiments confirmed that delivery of the *sspC* gene to cells via a plasmid, and following expression of

- 46 -

SspC, results in a massive reduction in cell viability. By 24 hours post-induction, viability of cells carrying the pET/PIP vector increase slightly as a result of host and/or plasmid mutations which impair SspC expression.

TABLE 2: Growth of strain PTL14 containing the *sspC* gene within pET24d (Novagen) in the absence (uninduced) or presence (induced) of IPTG (1 mM).

Time (h) (post-induction)	OD ₆₀₀		cfu/ml	
	Uninduced cells	Induced cells	Uninduced cells	Induced cells
0	0.25	0.25	7.0×10^7	7.0×10^7
0.5	0.65	0.58	3.0×10^8	5.8×10^4
1.0	1.38	0.79	5.0×10^9	7.0×10^4
2.0	2.7	0.83	6.0×10^{11}	6.0×10^3
3.0	3.58	1.20	9.8×10^{11}	3.0×10^3
24	4.23	1.52	8.0×10^{11}	6.6×10^7

The observed reduction of cell viability in cells expressing *sspC* is supported by data obtained following isolation of plasmid DNA from strain PTL14 grown and induced or repressed as detailed above. As a negative control, *E. coli* strain NM522 was also transformed with plasmid pET/PIP (to give strain PTL38) since NM522 does not contain the T7 RNA polymerase promoter and thus no expression of *sspC* can occur. Plasmid DNA from strain PTL14 (induced and uninduced) and strain PTL38, grown in parallel, was isolated according to the protocol of Kieser (1984). In order to relax plasmid supercoiling, plasmid DNA from each sample (0.5-1 µg) was incubated with Topoisomerase I (2 Units) for 2 h at 37 °C. The DNA was

- 47 -

then resolved by TAE agarose gel electrophoresis (5 h at 4.5 V/cm) in the presence of 0.06 µg/ml ethidium bromide (Keller, 1975). Following visualization by UV transillumination the gel was photographed as shown in Figure 13, which shows banding patterns of plasmid DNA prepared from strains grown ± production of SspC. The lanes are as follows

Lane 1	1 kb DNA ladder (0.25 µg total DNA)
Lane 2	Uninduced pET/PIP in <i>E. coli</i> strain BL21 □DE3 (PTL14)
Lane 3	Induced pET/PIP in <i>E. coli</i> strain BL21 □DE3 (PTL14)
Lane 4	Induced pET/PIP in <i>E. coli</i> strain BL21 □DE3 (PTL14) duplicate prep
Lane 5	Uninduced pET/PIP in <i>E. coli</i> strain NM522 (PTL38)

By comparison with pET/PIP DNA prepared from strain PTL38, there is a clear change in the plasmid DNA forms in the presence of SspC which is more markedly pronounced under conditions of induction (lanes 3 and 4). A much less marked alteration in profile is also present under conditions of leaky T7 RNA polymerase expression in the uninduced sample (lane 2). The chief profile changes associated with the high level of SspC expression are:

- i) Retardation of the monomer supercoiled form (1m S/C) (lanes 3 and 4) relative to the uninduced strain BL21 (lane 2) and strain PTL38 (lane 5).
- ii) Generation of diffuse bands running behind the monomer linear/open circular form (lanes 3 and 4).

- 48 -

The retardation of the monomeric supercoiled plasmid pET/PIP form when T7 RNA polymerase expression is induced (lanes 3 and 4) and, in particular, the diffuse bands in lanes 3 and 4 are characteristic of DNA protein complexes. The absence of these bands in plasmid DNA from uninduced cells (lane 5) is consistent with the retardation and diffuse bands being formed by complexes between pET/PIP DNA and SspC protein.

These data indicate that SspC expressed from a plasmid form can also be regarded as having potential application in pesticide or GM plant applications.

4. To demonstrate the importance of level of expression of *sspC*, a lambda phage has been constructed with the *sspC* gene inserted within the S gene but utilising the T7 RNA polymerase ribosome binding site. This strain (ST7PC) was constructed in an identical way to SPPC-Lambda except the T7 rbs is substituted for the native *sspC* rbs. Following the protocol used for SPPC-lambda infection, infecting cells with ST7PC-lambda results in a temporally accelerated loss of viability. For example, in a typical experiment, a $\geq 95\%$ reduction in cell viability is seen by 1 hour post infection, with a $\geq 99\%$ reduction within 3 h (see Table 3). These results indicate that utilizing an alternative rbs provide a means to modulate expression levels of SspC.

- 49 -

TABLE 3: Viability of cells following infection with
ST7PC-lambda

Time (h)	OD ₆₀₀	cfu/ml
pre-infection	0.39	3.2×10^8
post-infection	0.15	3.5×10^7
1 h post-infection	0.18	3.7×10^6
2 h post-infection	0.37	3.0×10^6
3 h post-infection	0.34	7.2×10^5
4 h post-infection	0.45	6.8×10^5
5 h post-infection	0.47	6.2×10^5

APPENDIX 1

A list of all the α/β type SASP which have been sequenced to date together with their related protein sequences

Bacillus subtilis

SASP A mannngnsn nllvpgaqa idqmkleias efgvnlgadt tsrangsvgg eitkrlvsfa qqnmgggqf(SEQ ID NO:26)
SASP B manqnssndl lvpgaqaaid qmkleiasef gvnlgadtts rangsvggei tkrlvsfaqq qmggrvq(SEQ ID NO:27)
SASP C maqqsrrsrn nnndlllpqa asaieqmkle iasefgvqlg aettstrangs vggeitkrlvr laqqnmggq fh(SEQ ID NO:28)
SASP D masrnklvvp gveqaldqfk levaqefgvn lgsdtvaran gsvggemtkr lvqqaqsqln gttk(SEQ ID NO:29)

Bacillus megaterium

SASP A mantnklvap gsaaaidqmk yeiasefgvn lgpeataran gsvggeitkr lvqmaeqqlg gk(SEQ ID NO:30)
SASP C manyqnasnr nssnklvapg aqaaidqmkf eiaasefgvnl gpdataarang svggeitkrl vqlaeqnlgg ky(SEQ ID NO:31)
SASP C1 mannssnnn ellvygaeqa idqmkyeias efgvnlgadt tarangsvgg eitkrlvqla eqqlgggrf(SEQ ID NO:32)
SASP C2 mannkssnnn ellvygaeqa idqmkyeias efgvnlgadt tarangsvgg eitkrlvqla eqqlgggrsk ttl(SEQ ID NO:33)
SASP C3 martnkl1tp gveqfldqyk yeiaqefgvt lgsdtaarsn gsvggeitkr lvqqaqahls gstqk(SEQ ID NO:34)
SASP C4 mannkssnnn ellvygaeqa idqmkyeias efgvnlgadt tarangsvgg eitkrlvqla eqqlgggrf(SEQ ID NO:35)
SASP C5 mansrnkssn elavhgaqqa idqmkyeias efgvtlgpdt tarangsvgg eitkrlvqma eqqlgggrsk sls(SEQ ID NO:36)
SASP C-1 mannssnnn ellvygaeqa idqmkyeias efgvnlgadt tarangsvgg eitkrlvqla eqlggggrf(SEQ ID NO:37)
SASP C-2 mannkssnnn ellvygaeqa idqmkyeias efgvnlgadt tarangsvgg eitkrlvqla eqlggggrskt tl(SEQ ID NO:38)

Bacillus cereus

SASP 1 mgknngsrn evlvrgaeqa ldqmkyeiaq efgvqlgadt tarsngsvgg eitkrlvama eqqlgggranr (SEQ ID NO:39)
SASP 2 msrstnklav pgaesaldqm kyeiaqefgv qlgadataara ngsvggeitk rlvslaeqqql ggyqk(SEQ ID NO:40)
SASP C5 mlfiniqrye sdtneilisa ttstieqmky eiaafelgvtl gpdtsghlqm vriggeitkr lvрмаekqlt ggyrlh(SEQ ID NO:41)

Bacillus stearothermophilus

SASP 1 mpnqsgsnss nql1vpgaqa vidqmkfeia sefgvnlgae ttsrangsvg geitkrlvsf aqqqmgggvq (SEQ ID NO:42)

Bacillus firmus

SASP A mannssnql vvpvgvqqald qmkyeiaasef gvqlgpdata rangsvggei tkrlvqmaeq qmggyqk(SEQ ID NO:43)

Clostridium bifermentans

SASP α tttnnnntkav peakaaalkqm kleianelgi snydtadkgn mtarqngyvg gymtkklvem aeqqmsgqqr (SEQ ID NO:44)
SASP β stkkavpeak aalnqmklei anelglsnys svdkgnltar qngyvvggymt kklvemaerq msgk(SEQ ID NO:45)

Clostridium perfringens

SASP 1 mkslvppeak nglskfknev arelgvpfsd yngdlssrqc gsvggemvkr mveayesqik(SEQ ID NO:46)
SASP C1 msqhlvppeak nglskfknev aaemgvpfsd yngdlsskqc gsvggemvkr mveqyekgi(SEQ ID NO:47)
SASP C2 msqhlvppeak nglskfknev anemgvpfsd yngdlssrqc gsvggemvkr mvekyeqsmk(SEQ ID NO:48)

Sporosarcina halophila

SASP 1 mannnssnel vvpgvqqald qmkyeiaqef gvqlgadsts rangsvggei tkrlvqmaeq qfggqqygqq qk(SEQ ID NO:49)

Sporocarcina ureae

SASP 1 mtnnnnnsn qllvpvgvqqa inqmkeeian efgvnlgpds tsrangsvgg eitkrlvrqa qsqmngytk(SEQ ID NO:50)
SASP 2 mpnnnnssnql lvpgvqqaln qmkeeiasef gvqlgpdass rangsvggei tkrlvrqaqs qmngytk(SEQ ID NO:51)

Thermoactinomyces thalpophilus

SASP 1 maqqgrnrss nqllvagaaq aidqmkeia gefgvtlgad ttsrangsvg geitkrlvsl aqqqlgggts f(SEQ ID NO:52)

APPENDIX 2

An alignment of α/β type SASP protein sequences known to date.

SASP A	(1)	mannsgnsnnllvpgaacaqldqmkleia	sefgvnl	gadtt	srangsv	ggeit	kr	lv	sfaqqnm	ggqf	(SEQ ID NO:26)		
SASP B	(1)	manqnssndllvpgaacaqldqmkleia	sefgvnl	gadtt	srangsv	ggeit	kr	lv	sfaqqm	ggrvq	(SEQ ID NO:27)		
SASP C	(1)	maqsrsrnnndlllpqaasaieqmkleia	sefgvql	gaett	srangsv	ggeit	kr	lv	rlaqnm	ggqfh	(SEQ ID NO:28)		
SASP D	(1)	masrnklvvp	gveqaldqfk	levaqef	gvnl	gsdt	varangsv	ggemt	kr	lv	qqaqslngttk	(SEQ ID NO:29)	
SASP A	(2)	mantnklvap	gsaaaidqmkyeia	sefgvnl	gpeat	arangsv	ggeit	kr	lv	qmaeqql	ggk	(SEQ ID NO:30)	
SASP C	(2)	manyqnasnrnssnklvap	gaqaaidqmkyeia	sefgvnl	gpdatarangsv	ggeit	kr	lv	qlaeqnl	ggky	(SEQ ID NO:31)		
SASP C1	(2)	mannssnnnellvygae	qaaidqmkyeia	sefgvnl	gadttarangsv	ggeit	kr	lv	qlaeqql	gggrf	(SEQ ID NO:32)		
SASP C2	(2)	mannkssnnnellvygae	qaaidqmkyeia	sefgvnl	gadttarangsv	ggeit	kr	lv	qlaeqql	gggrskttl	(SEQ ID NO:33)		
SASP C3	(2)	martnkl	lltpgveqfldqy	kyeia	sefgvnl	gsdt	aarsngsv	ggeit	kr	lv	qqaqah	lsgstqk	(SEQ ID NO:34)
SASP C4	(2)	mannkssnnnellvygae	qaaidqmkyeia	sefgvnl	gadttarangsv	ggeit	kr	lv	qlaeqql	gggrf	(SEQ ID NO:35)		
SASP C5	(2)	mansrnkssnellavhga	qaqaaidqmkyeia	sefgvnl	gpdttarangsv	ggeit	kr	lv	qmaeqql	gggrskls	(SEQ ID NO:36)		
SASP C-1	(2)	mannssnnnellvygae	qaaidqmkyeia	sefgvnl	gadttarangsv	ggeit	kr	lv	qlaeqql	gggrf	(SEQ ID NO:37)		
SASP C-2	(2)	mannkssnnnellvygae	qaaidqmkyeia	sefgvnl	gadttarangsv	ggeit	kr	lv	qlaeqql	gggrskttl	(SEQ ID NO:38)		
SASP 1	(3)	mgknnsgsrnevlvrgae	qaaidqmkyeia	sefgvnl	gadttarangsv	ggeit	kr	lv	vamaeqql	gggranr	(SEQ ID NO:39)		
SASP 2	(3)	msrstnklavp	gaesaldqmkyeia	sefgvnl	gadatarangsv	ggeit	kr	lv	slaeqql	ggvqk	(SEQ ID NO:40)		
SASP 1	(4)	mpnqsgsnnsl	llvpgaacaqldqmkyeia	sefgvnl	gaett	srangsv	ggeit	kr	lv	sfaqqm	ggvq	(SEQ ID NO:42)	
SASP A	(5)	mannssnqlvvp	gvqqaldqmkyeia	sefgvnl	gpdatarangsv	ggeit	kr	lv	qmaeqqm	ggyqk	(SEQ ID NO:43)		
SASP 1	(6)	mannssnelvvp	gvqqaldqmkyeia	sefgvnl	gadst	rangsv	ggeit	kr	lv	qmaeqqf	ggqygqqk	(SEQ ID NO:49)	
SASP 1	(7)	mtnnnnsnql	llvpgvqqainqm	keeeianef	gvnl	gpdst	rangsv	ggeit	kr	lv	rqaqsmn	gytk	(SEQ ID NO:50)
SASP 2	(7)	mpnnnssnql	llvpgvqqainqm	keeeianef	gvnl	gpdass	rangsv	ggeit	kr	lv	rqaqsmn	gytk	(SEQ ID NO:51)
SASP 1	(8)	maqggrnrssnql	lvagaacaqldqmkyeia	sefgvnl	gadtt	rangsv	ggeit	kr	lv	slaqql	gggtstf	(SEQ ID NO:52)	
* * * * *													
* * * * *													

Key

- | | | | |
|-----|------------------------------------|-----|---------------------------------------|
| (1) | <i>Bacillus subtilis</i> | (5) | <i>Bacillus firmus</i> |
| (2) | <i>Bacillus megaterium</i> | (6) | <i>Sporosarcina halophila</i> |
| (3) | <i>Bacillus cereus</i> | (7) | <i>Sporocarcina ureae</i> |
| (4) | <i>Bacillus stearothermophilus</i> | (8) | <i>Thermoactinomyces thalpophilus</i> |
- * Residues conserved in *Bacillus* and *Sporosarcina* SASP as well as the *Thermoactinomyces* SASP.

SASP α	(9)	ttnnnntkavpeakaalkqmkleianelgisnydtadkgnmtarqngyvggymtkklvemaeqmsgqqr (SEQ ID NO:44)
SASP β	(9)	stkkavpeakaalnqmkleianelglslsnyesvdkgnltarqngyvggymtkklvemaerqmsgk (SEQ ID NO:45)
SASP 1	(10)	mskslvpeaknglskfknevarrelgvpfbsdynygd--lssrqcgsvggemvkrmvaeayesqik (SEQ ID NO:46)
SASP C1	(10)	msqhlvpeaknglskfknevaaemgvpfbsdynygd--lsskqcgsvggemvkrmvveqyekgi (SEQ ID NO:47)
SASP C2	(10)	msqhlvpeaknglskfknevanemgvpfbsdynygd--lssrqcgsvggemvkrmvvekyeqsmk (SEQ ID NO:48)
		000000 0 * * * * * 0 * * * * 0 * * * 0 * * 0 0

Key

(9) *Clostridium bifermentans*
(10) *Clostridium perfringens*

* Residues conserved in *Bacillus*, *Sporosarcina* and *Clostridia* SASP as well as the *Thermoactinomyces* SASP.

0 Residues conserved in *Clostridia* SASP

- 54 -

APPENDIX 3

DNA sequence of *sspC* encoding SASP C from *Bacillus subtilis* strain 168 (obtained from Subtilist at the Institut Pasteur).

(SEQ ID NO:53)

```
atggctcaac aaagtagatc aagatcaaac aacaataatg atttactaat    50
tcctcaagca gcttcagcta ttgaacaaat gaaacttgaa atagcttctg    100
agtttggtgt tcaattaggc gctgagacta catctcgtgc aaacggttca    150
gttggtggag aaatcactaa acgttttagtt cgcttagctc aacaaaacat    200
gggcggtcaa tttcattaat ttatgagggg gataattccc ctctcttttt    250
taagtcttct ctaaattccat ac                                     272
```

Note:

The *sspC* gene extends from 1-219 (inclusive)

The terminator sequence extends from 225-243 (inclusive)

- 55 -

APPENDIX 4

A list of common pathogens and some of their phages. (This list is representative but not exhaustive).

Coliphages:

Bacteriophage lambda
Bacteriophage 933W (*Escherichia coli* O157:H7)
Bacteriophage VT2-Sa (*E. coli* O157:H7)
Coliphage 186
Coliphage P1
Coliphage P2
Coliphage N15
Bacteriophage T3
Bacteriophage T4
Bacteriophage T7
Bacteriophage KU1

Bacteriophages of *Salmonella* spp

Bacteriophage Felix
Bacteriophage P22
Bacteriophage L
Bacteriophage 102
Bacteriophage 31
Bacteriophage F0
Bacteriophage 14
Bacteriophage 163
Bacteriophage 175
Bacteriophage Vir
Bacteriophage ViVI
Bacteriophage 8
Bacteriophage 23
Bacteriophage 25
Bacteriophage 46
Bacteriophage E15
Bacteriophage E34
Bacteriophage 9B

Bacteriophages of *Shigella dysenteriae*

Bacteriophage ϕ 80
Bacteriophage P2
Bacteriophage 2
Bacteriophage 37

- 56 -

Bacteriophages of *Vibrio cholerae*

Bacteriophage fs-2
Bacteriophage 138
Bacteriophage 145
Bacteriophage 149
Bacteriophage 163

Bacteriophages of *Mycoplasma arthritidis*

Bacteriophage MAV1

Bacteriophages of *Streptococci*

Bacteriophage CP-1
Bacteriophage ϕ Xz40
Bacteriophage 1A
Bacteriophage 1B
Bacteriophage 12/12
Bacteriophage 113
Bacteriophage 120
Bacteriophage 124

Bacteriophages of *Pseudomonas aeruginosa*

Bacteriophage D3
Bacteriophage ϕ CTX
Bacteriophage PP7

Bacteriophages of *Haemophilus influenzae*

Bacteriophage S2
Bacteriophage HP1
Bacteriophage flu
Bacteriophage Mu

Bacteriophages of *Staphylococcus aureus*

Bacteriophage Twort
Bacteriophage tIII-29S
Bacteriophage ϕ PVL
Bacteriophage ϕ PV83
Bacteriophage ϕ 11
Bacteriophage ϕ 12
Bacteriophage ϕ 13
Bacteriophage ϕ 42

- 57 -

Bacteriophage ϕ 812
Bacteriophage K
Bacteriophage P3
Bacteriophage P14
Bacteriophage UC18
Bacteriophage 15
Bacteriophage 17
Bacteriophage 29
Bacteriophage 42d
Bacteriophage 47
Bacteriophage 52
Bacteriophage 53
Bacteriophage 79
Bacteriophage 80
Bacteriophage 81
Bacteriophage 83
Bacteriophage 85
Bacteriophage 93
Bacteriophage 95
Bacteriophage 187

Bacteriophages of Chlamydia

Bacteriophage ϕ CPAR39

Mycobacteriophage

Bacteriophage L5
Bacteriophage LG
Bacteriophage D29
Bacteriophage Rv1
Bacteriophage Rv2
Bacteriophage DSGA

Bacteriophages of *Listeria monocytogenes*

Bacteriophage A118
Bacteriophage 243
Bacteriophage A500
Bacteriophage A511
Bacteriophage 10
Bacteriophage 2685
Bacteriophage 12029
Bacteriophage 52
Bacteriophage 3274

Bacteriophages of *Klebsiella pneumoniae*

Bacteriophage 60

Bacteriophage 92

Bacteriophages of *Yersinia pestis*

Bacteriophage R

Bacteriophage Y

Bacteriophage P1

APPENDIX 5

A list of bacteriophage receptors and ligands from bacteria and other cells. (This list is representative but not exhaustive).

Receptor/ligand	Phage
Porins (OmpA, OmpC and LamB etc.) (e.g. proteins involved in transport of specific substrates: phosphates, nucleosides, iron, vitamin B12, maltose and maltodextrins)	Lambda and other coliphages such as T- Even coliphage Ox2, Host range mutant of Ox2 coliphage
Peptidoglycan	Phage A25 (Group A Streptococci) <i>Listeria monocytogenes</i> phage Coliphage T5
N-acetylglucosamine and rhamnose substituents of teichoic acids	<i>Listeria monocytogenes</i> Phage
L-rhamnose	Phage PL-1 (<i>Lactobacillus casei</i>)
Exopolysaccharides and Lipopolysaccharides	Siphovirus Phage NM8 (<i>Rhizobium meliloti</i>) Host range mutant of Ox2 coliphage
Teichoic acid	Phages SP 50 and ϕ 25 (<i>Bacillus subtilis</i>)

Modified receptor/ligand affinities

Fibroblast growth factor receptor	Phage M13 displaying FGF2 on coats
Epidermal growth factor receptor	Phage M13 displaying EGF on coats

- 60 -

APPENDIX 6

Sequence data from SSPC-LAMBDA (positive strand only), obtained using primers:

13F1 and B30 (see Figure 7, Section A 11):

(SEQ ID NO:54)

Front end of λ fragment originating from pB/IPSAPOC (base 44660)

CTAGTTGGTCACTTCGACGTATCGTCTGGA ACTCCAACCATCGCAGGCAGAGAGGTCTG
 CAAAATGCAATCCCGAAACAGTTCGCAGGTAATAGTTAGAGCCTGCATAACGGTTTCGG
 GATTTTTTATATCTGCACAACAGGTAAGAGCATTGAGTCGATAATCGTGAAGAGTCGGC
 GAGCCTGGTTAGCCAGTGCTCTTCCGTTGTGCTGAATTAAGCGAATACCGGAAGCAGA
 ACCGGATCACCAAATGCGTACAGGCGTCATCGCCGCCAGCAACAGCACAACCCAAACT
 GAGCCGTAGCCACTGTCTGTCCTGAATTCATTAGTAATAGTTACGCTGCGGCCTTTTAC
 ACATGACCTTCGTGAAAGCGGGTGGCAGGAGGTCGCGCTAACAACTCCTGCCGTTTTG
 CCCGTGCATATCGGTCACGAACAAATCTGATTACTAAACACAGTAGCCTGGATTTGTTC
 TATCAGTAATCGACCTTATTCCTAATTAAATAGAGCAAATCCCCTTATTGGGGGTAAGA

Start of *sspC* gene

CATGACCATGGCTCAACAAAGTAGATCAAGATCAAACAACAATAATGATTTACTAATTC

NcoI

CTCAAGCAGCTTCAGCTATTGAACAAATGAACTTGAAATAGCTTCTGAGTTTGGTGTT
 CAATTAGGCGCTGAGACTACATCTCGTGCAAACGGTTCAGTTGGTGGAGAAATCACTAA

End of *sspC* gene

ACGTTTAGTTCGCTTAGCTCAACAAAACATGGGCGGTCAATTTCAATTAACTAGTGCAC

End of

Cm^r gene fragment

SpeI

CAATAACTGCCTTAAAAAAATTACGCCCCGCCCTGCCACTCATCGCAGTACTGTTG

- 61 -

B54 and B55:

(SEQ ID NO:55)

TGTTTCAGCTACTGACGGGGTGGTGGCGTAACGGCAAAGCACCGCCGGACATCAGCGCTA

Start of Cm^r gene fragment λ base 45499

GCGGAGTGTATACTGGACTAGTGAAATCAATAATCAACGTAAGGCGTTCCTCGATATGC

SpeI

TGGCGTGGTCGGAGGGAACTGATAACGGACGTCAGAAAACCAGAAATCATGGTTATGAC

GTCATTGTAGGCGGAGAGCTATTTACTGATTACTCCGATCACCTCGCAAACCTTGTCAC

GCTAAACCCAAAACCTCAAATCAACAGGCGCCGGACGCTACCAGCTTCTTTCCCGTTGGT

GGGATGCCTACCGCAAGCAGCTTGGCCTGAAAGACTTCTCTCCGAAAAGTCAGGACGCT

GTGGCATTGCAGCAGATTAAGGAGCGTGGCGCTTTACCTATGATTGATCGTGGTGATAT

CCGTCAGGCAATCGACCGTTGCAGCAATATCTGGGCTTCACTGCCGGGCGCTGGTTATG

GTCAGTTCGAGCATAAGGCTGACAGCCTGATTGCAAATTCAAAGAAGCGGGCGGAACG

End of λ fragment originating from pB/IPSAPOC (base 45972)

GTCAGAGAGATTGATGTATGAGCAGAGTCACCGCG

- 62 -

APPENDIX 7

Sequence data from pET/PIP (positive strand only), obtained using primers:

T3 and B8

(SEQ ID NO:56)

T7 promoter
→
CTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTC
T7 rbs Start of *sspC* gene
CCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGCTCAACAAAGT
NcoI
AGATCAAGATCAAACAACAATAATGATTTACTAATTCCTCAAGCAGCTTCAGCTATTGAACA
AATGAAACTTGAAATAGCTTCTGAGTTTGGTGTTC AATTAGGCGCTGAGACTACATCTCGTG
CAAACGGTTCAGTTGGTGGAGAAATCACTAAACGTTTAGTTCGCTTAGCTCAA
End of *sspC* ORF
←
CAAAACATGGGCGGTCAATTCATTAATTTATGAGGGGGATAATCCCCTCTCTTTTTT
End of *sspC* termination sequence
←
AAGTCTTCTCTAAATCCATACCTCGAGCACCACCACCACCACC ACTGA
XhoI

- 63 -

REFERENCES

- Cao, J., Y. Sun, T. Berlindh, B. Mellgard, Z. Li, B. Mardh and S. Mardh. 2000. *Biochim. Biophys. Acta.* **1474**:107-113.
- Donnellan, J.E. jnr. and R. B. Setlow, 1965. *Science.* **149**:308-310
- Fairhead, H. and P. Setlow. 1991. *J. Bacteriol.* **174**:2874-2880
- Fairhead, H., B. Setlow and P. Setlow. 1993. *J. Bacteriol.* **175**:1367-1374.
- Hawes Hackett, R. and P. Setlow. 1987. *J. Bacteriol.* **169**:1985-1992.
- Hayes, C.S., Z-Y. Peng and P. Setlow. 2000. *J. Biol. Chem.* In press.
- Kassner, P.D., A.A. Burg, A. Baird and D. Larocca. 1999. *Biochem. Biophys. Res. Commun.* **264**:921-928.
- Keller, W. 1975. Determination of the number of superhelical turns in simian virus 40 DNA by gel electrophoresis. *Proc. Nat. Acad. Sci. USA.* **72**:4876-4880.
- Kieser, T. 1984. Factors affecting the isolation of CCC-DNA from *Streptomyces lividans* and *E. coli*. *Plasmid* **12**:19-36.
- Larocca, D., A. Witte, W. Johnson, C.G. Pierce and A. Baird. 1998. *Hum. Gene Ther.* **9**:2393-2399.
- Larocca, D., P. Kassner, A. Witte, R. Ladner, G.F. Pierce and A. Baird. 1999. *FASEB J.* **13**:727-734.
- Mohr, S.C., N.V.H.A. Sokolov, C. He and Peter Setlow. 1991. *Proc. Natl. Acad. Sci. USA* **88**: 77-81.
- Nicholson, W.L., and P. Setlow, 1990. *J. Bacteriol.* **172**:7-14
- Nicholson, W.L., B. Setlow and P. Setlow. 1990a. *J. Bacteriol.* **172**:6900-6906.

- 64 -

- Nicholson, W.L., B. Setlow and P. Setlow. 1990b. *J. Bacteriol.* **173**:1642-1653
- Nicholson, W.L., B. Setlow and P. Setlow. 1991. *Proc. Natl. Acad. Sci. USA* **88**: 8288-8292.
- Pohle, W. and H. Fritzche. 1980. *Nucleic Acids Res.* **8**:2527-2535.
- Poul, M. and J.D. Marks. 1999. *J.Mol.Biol.* **288**:203-211
- Sambrook, J., E.F. Fritsch, T. Maniatis, 1989. In Molecular Cloning: A Laboratory Manual, CSHL Press
- Setlow, B., A.R. Hand and P. Setlow. 1991. *J. Bacteriol.* **173**:1642-1653.
- Setlow, B., D. Sun and P. Setlow. 1992. *J. Bacteriol.* **174**:2312-2322.
- Setlow, P. 1988. *Ann. Rev. Microbiol.* **42**:319-338.
- de Vries, G.E., C.K. Raymond and R.A. Ludwig. 1984 *Proc. Natl. Acad. Sci. USA* **81**:6080-6084.

- 65 -

SEQUENCE LISTING

<110> Phico Therapeutics Limited

<120> Polypeptide and uses thereof

<130> 13014-21

<140> CA 2,428,662

<141> 2001-11-16

<150> GB 028130.3

<151> 2000-11-17

<160> 60

<170> PatentIn version 3.1

<210> 1

<211> 69

<212> PRT

<213> Artificial sequence

<220>

<223> typical polypeptide having alpha/beta SASP activity

<400> 1

Met	Ala	Asn	Asn	Asn	Ser	Ser	Asn	Ser	Asn	Glu	Leu	Leu	Val	Pro	Gly
1				5					10					15	

Ala	Glu	Gln	Ala	Ile	Asp	Gln	Met	Lys	Tyr	Glu	Ile	Ala	Ser	Glu	Phe
			20					25					30		

Gly	Val	Asn	Leu	Gly	Ala	Asp	Thr	Thr	Ala	Arg	Ala	Asn	Gly	Ser	Val
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

- 66 -

35

40

45

Gly Gly Glu Ile Thr Lys Arg Leu Val Gln Leu Ala Glu Gln Gln Leu
50 55 60

Gly Gly Gly Thr Lys
65

<210> 2

<211> 26

<212> DNA

<213> Artificial sequence

<220>

<223> primer sequence

<400> 2

aactgcaggg tcacttcgac gtatcg

26

<210> 3

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> primer sequence

<400> 3

gctctagagc tcatacatca atctc

25

<210> 4

<211> 22

<212> DNA

<213> Artificial sequence

- 67 -

<220>

<223> primer sequence

<400> 4

catgccatgg tcatgtctta cc

22

<210> 5

<211> 17

<212> DNA

<213> Artificial sequence

<220>

<223> primer sequence

<400> 5

catcttcatg tcttacc

17

<210> 6

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> primer sequence

<400> 6

ggactagtga aatcaataat caacg

25

<210> 7

<211> 20

<212> DNA

<213> Artificial sequence

- 68 -

<220>

<223> primer sequence

<400> 7

gctcaacaaa gtagatcaag

20

<210> 8

<211> 29

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 8

catgccatgg ctcaacaaag tagatcaag

29

<210> 9

<211> 24

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 9

ggactagttt aatgaaattg accg

24

<210> 10

<211> 25

<212> DNA

<213> ARTIFICIAL SEQUENCE

- 69 -

<220>

<223> primer sequence

<400> 10

ggtactgatg tgatggctgc tatgg

25

<210> 11

<211> 23

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 11

gcaacatcat cacgcagagc atc

23

<210> 12

<211> 21

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 12

caacagtact gcgatgagtg g

21

<210> 13

<211> 18

<212> DNA

<213> ARTIFICIAL SEQUENCE

- 70 -

<220>

<223> primer sequence

<400> 13

gtagtgagat gaaaagag

18

<210> 14

<211> 21

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 14

gtaggtaatg gcgttatcac g

21

<210> 15

<211> 22

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 15

ggtggtgcgt aacggcaaaa gc

22

<210> 16

<211> 24

<212> DNA

<213> ARTIFICIAL SEQUENCE

- 71 -

<220>

<223> primer sequence

<400> 16

cgggatccga ttcaaacaag cttg

24

<210> 17

<211> 25

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 17

cgggatccca tcttcatgtc ttac

25

<210> 18

<211> 28

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 18

aactgcagcg ctgtgacgat gctaattcc

28

<210> 19

<211> 24

<212> DNA

<213> ARTIFICIAL SEQUENCE

- 72 -

<220>

<223> primer sequence

<400> 19

aactgcagga ttcaaacaag cttg

24

<210> 20

<211> 26

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 20

aacaggcgcc gattcaaaca agcttg

26

<210> 21

<211> 22

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 21

aacaggcgcc agtatacact cc

22

<210> 22

<211> 17

<212> DNA

<213> ARTIFICIAL SEQUENCE

- 73 -

<220>

<223> primer sequence

<400> 22

ctatttactg attactc

17

<210> 23

<211> 17

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 23

cttaatctgc tgcaatg

17

<210> 24

<211> 32

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> primer sequence

<400> 24

ggactagtcg acgcgtttta tgaaattgac cg

32

<210> 25

<211> 24

<212> DNA

<213> ARTIFICIAL SEQUENCE

- 74 -

<220>

<223> primer sequence

<400> 25

cgacgcgtga ttcaaacaag cttg

24

<210> 26

<211> 69

<212> PRT

<213> Bacillus subtilis

<400> 26

Met	Ala	Asn	Asn	Asn	Ser	Gly	Asn	Ser	Asn	Asn	Leu	Leu	Val	Pro	Gly
1				5					10					15	

Ala	Ala	Gln	Ala	Ile	Asp	Gln	Met	Lys	Leu	Glu	Ile	Ala	Ser	Glu	Phe
		20						25					30		

Gly	Val	Asn	Leu	Gly	Ala	Asp	Thr	Thr	Ser	Arg	Ala	Asn	Gly	Ser	Val
		35					40					45			

Gly	Gly	Glu	Ile	Thr	Lys	Arg	Leu	Val	Ser	Phe	Ala	Gln	Gln	Asn	Met
	50					55					60				

Gly	Gly	Gly	Gln	Phe
65				

<210> 27

<211> 67

<212> PRT

<213> Bacillus subtilis

<400> 27

Met Ala Asn Gln Asn Ser Ser Asn Asp Leu Leu Val Pro Gly Ala Ala

- 75 -

1		5		10		15									
Gln	Ala	Ile	Asp	Gln	Met	Lys	Leu	Glu	Ile	Ala	Ser	Glu	Phe	Gly	Val
			20					25					30		
Asn	Leu	Gly	Ala	Asp	Thr	Thr	Ser	Arg	Ala	Asn	Gly	Ser	Val	Gly	Gly
		35					40					45			
Glu	Ile	Thr	Lys	Arg	Leu	Val	Ser	Phe	Ala	Gln	Gln	Gln	Met	Gly	Gly
	50					55					60				
Arg	Val	Gln													
65															

<210> 28

<211> 72

<212> PRT

<213> Bacillus subtilis

<400> 28

Met	Ala	Gln	Gln	Ser	Arg	Ser	Arg	Ser	Asn	Asn	Asn	Asn	Asp	Leu	Leu
1				5					10					15	
Ile	Pro	Gln	Ala	Ala	Ser	Ala	Ile	Glu	Gln	Met	Lys	Leu	Glu	Ile	Ala
			20					25					30		
Ser	Glu	Phe	Gly	Val	Gln	Leu	Gly	Ala	Glu	Thr	Thr	Ser	Arg	Ala	Asn
		35					40					45			
Gly	Ser	Val	Gly	Gly	Glu	Ile	Thr	Lys	Arg	Leu	Val	Arg	Leu	Ala	Gln
	50					55					60				
Gln	Asn	Met	Gly	Gly	Gln	Phe	His								
65					70										

<210> 29

<211> 64

- 76 -

<212> PRT

<213> Bacillus subtilis

<400> 29

Met	Ala	Ser	Arg	Asn	Lys	Leu	Val	Val	Pro	Gly	Val	Glu	Gln	Ala	Leu
1				5					10					15	

Asp	Gln	Phe	Lys	Leu	Glu	Val	Ala	Gln	Glu	Phe	Gly	Val	Asn	Leu	Gly
			20					25					30		

Ser	Asp	Thr	Val	Ala	Arg	Ala	Asn	Gly	Ser	Val	Gly	Gly	Glu	Met	Thr
		35					40					45			

Lys	Arg	Leu	Val	Gln	Gln	Ala	Gln	Ser	Gln	Leu	Asn	Gly	Thr	Thr	Lys
	50					55					60				

<210> 30

<211> 62

<212> PRT

<213> Bacillus megaterium

<400> 30

Met	Ala	Asn	Thr	Asn	Lys	Leu	Val	Ala	Pro	Gly	Ser	Ala	Ala	Ala	Ile
1				5					10					15	

Asp	Gln	Met	Lys	Tyr	Glu	Ile	Ala	Ser	Glu	Phe	Gly	Val	Asn	Leu	Gly
			20					25					30		

Pro	Glu	Ala	Thr	Ala	Arg	Ala	Asn	Gly	Ser	Val	Gly	Gly	Glu	Ile	Thr
		35					40					45			

Lys	Arg	Leu	Val	Gln	Met	Ala	Glu	Gln	Gln	Leu	Gly	Gly	Lys
	50					55					60		

<210> 31

- 77 -

<211> 72

<212> PRT

<213> Bacillus megaterium

<400> 31

Met	Ala	Asn	Tyr	Gln	Asn	Ala	Ser	Asn	Arg	Asn	Ser	Ser	Asn	Lys	Leu
1				5					10					15	

Val	Ala	Pro	Gly	Ala	Gln	Ala	Ala	Ile	Asp	Gln	Met	Lys	Phe	Glu	Ile
			20					25					30		

Ala	Ser	Glu	Phe	Gly	Val	Asn	Leu	Gly	Pro	Asp	Ala	Thr	Ala	Arg	Ala
		35					40					45			

Asn	Gly	Ser	Val	Gly	Gly	Glu	Ile	Thr	Lys	Arg	Leu	Val	Gln	Leu	Ala
	50					55					60				

Glu	Gln	Asn	Leu	Gly	Gly	Lys	Tyr
65					70		

<210> 32

<211> 69

<212> PRT

<213> Bacillus megaterium

<400> 32

Met	Ala	Asn	Asn	Asn	Ser	Ser	Asn	Asn	Asn	Glu	Leu	Leu	Val	Tyr	Gly
1				5					10					15	

Ala	Glu	Gln	Ala	Ile	Asp	Gln	Met	Lys	Tyr	Glu	Ile	Ala	Ser	Glu	Phe
			20					25					30		

Gly	Val	Asn	Leu	Gly	Ala	Asp	Thr	Thr	Ala	Arg	Ala	Asn	Gly	Ser	Val
		35					40					45			

Gly	Gly	Glu	Ile	Thr	Lys	Arg	Leu	Val	Gln	Leu	Ala	Glu	Gln	Gln	Leu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

- 78 -

50

55

60

Gly Gly Gly Arg Phe
65

<210> 33

<211> 73

<212> PRT

<213> Bacillus megaterium

<400> 33

Met Ala Asn Asn Lys Ser Ser Asn Asn Asn Glu Leu Leu Val Tyr Gly
1 5 10 15

Ala Glu Gln Ala Ile Asp Gln Met Lys Tyr Glu Ile Ala Ser Glu Phe
20 25 30

Gly Val Asn Leu Gly Ala Asp Thr Thr Ala Arg Ala Asn Gly Ser Val
35 40 45

Gly Gly Glu Ile Thr Lys Arg Leu Val Gln Leu Ala Glu Gln Gln Leu
50 55 60

Gly Gly Gly Arg Ser Lys Thr Thr Leu
65 70

<210> 34

<211> 65

<212> PRT

<213> Bacillus megaterium

<400> 34

Met Ala Arg Thr Asn Lys Leu Leu Thr Pro Gly Val Glu Gln Phe Leu
1 5 10 15

- 79 -

Asp Gln Tyr Lys Tyr Glu Ile Ala Gln Glu Phe Gly Val Thr Leu Gly
 20 25 30

Ser Asp Thr Ala Ala Arg Ser Asn Gly Ser Val Gly Gly Glu Ile Thr
 35 40 45

Lys Arg Leu Val Gln Gln Ala Gln Ala His Leu Ser Gly Ser Thr Gln
 50 55 60

Lys
 65

<210> 35

<211> 69

<212> PRT

<213> Bacillus megaterium

<400> 35

Met Ala Asn Asn Lys Ser Ser Asn Asn Asn Glu Leu Leu Val Tyr Gly
 1 5 10 15

Ala Glu Gln Ala Ile Asp Gln Met Lys Tyr Glu Ile Ala Ser Glu Phe
 20 25 30

Gly Val Asn Leu Gly Ala Asp Thr Thr Ala Arg Ala Asn Gly Ser Val
 35 40 45

Gly Gly Glu Ile Thr Lys Arg Leu Val Gln Leu Ala Glu Gln Gln Leu
 50 55 60

Gly Gly Gly Arg Phe
 65

<210> 36

<211> 73

<212> PRT

- 80 -

<213> Bacillus megaterium

<400> 36

Met	Ala	Asn	Ser	Arg	Asn	Lys	Ser	Ser	Asn	Glu	Leu	Ala	Val	His	Gly
1				5					10					15	

Ala	Gln	Gln	Ala	Ile	Asp	Gln	Met	Lys	Tyr	Glu	Ile	Ala	Ser	Glu	Phe
			20					25					30		

Gly	Val	Thr	Leu	Gly	Pro	Asp	Thr	Thr	Ala	Arg	Ala	Asn	Gly	Ser	Val
		35					40					45			

Gly	Gly	Glu	Ile	Thr	Lys	Arg	Leu	Val	Gln	Met	Ala	Glu	Gln	Gln	Leu
	50					55					60				

Gly	Gly	Gly	Arg	Ser	Lys	Ser	Leu	Ser
65					70			

<210> 37

<211> 68

<212> PRT

<213> Bacillus megaterium

<400> 37

Met	Ala	Asn	Asn	Asn	Ser	Ser	Asn	Asn	Asn	Glu	Leu	Leu	Val	Tyr	Gly
1				5					10					15	

Ala	Glu	Gln	Ala	Ile	Asp	Gln	Met	Lys	Tyr	Glu	Ile	Ala	Ser	Glu	Phe
			20					25					30		

Gly	Val	Asn	Leu	Gly	Ala	Asp	Thr	Thr	Ala	Arg	Ala	Asn	Gly	Ser	Val
		35					40					45			

Gly	Gly	Glu	Ile	Thr	Lys	Arg	Leu	Val	Gln	Leu	Ala	Glu	Gln	Leu	Gly
	50					55					60				

Gly	Gly	Arg	Phe
-----	-----	-----	-----

- 81 -

65

<210> 38

<211> 72

<212> PRT

<213> Bacillus megaterium

<400> 38

Met	Ala	Asn	Asn	Lys	Ser	Ser	Asn	Asn	Asn	Glu	Leu	Leu	Val	Tyr	Gly
1				5					10					15	

Ala	Glu	Gln	Ala	Ile	Asp	Gln	Met	Lys	Tyr	Glu	Ile	Ala	Ser	Glu	Phe
			20					25					30		

Gly	Val	Asn	Leu	Gly	Ala	Asp	Thr	Thr	Ala	Arg	Ala	Asn	Gly	Ser	Val
		35					40					45			

Gly	Gly	Glu	Ile	Thr	Lys	Arg	Leu	Val	Gln	Leu	Ala	Glu	Gln	Leu	Gly
	50					55					60				

Gly	Gly	Arg	Ser	Lys	Thr	Thr	Leu
65					70		

<210> 39

<211> 70

<212> PRT

<213> Bacillus cereus

<400> 39

Met	Gly	Lys	Asn	Asn	Ser	Gly	Ser	Arg	Asn	Glu	Val	Leu	Val	Arg	Gly
1				5					10					15	

Ala	Glu	Gln	Ala	Leu	Asp	Gln	Met	Lys	Tyr	Glu	Ile	Ala	Gln	Glu	Phe
			20					25					30		

- 82 -

Gly Val Gln Leu Gly Ala Asp Thr Thr Ala Arg Ser Asn Gly Ser Val
 35 40 45

Gly Gly Glu Ile Thr Lys Arg Leu Val Ala Met Ala Glu Gln Gln Leu
 50 55 60

Gly Gly Arg Ala Asn Arg
 65 70

<210> 40

<211> 65

<212> PRT

<213> Bacillus cereus

<400> 40

Met Ser Arg Ser Thr Asn Lys Leu Ala Val Pro Gly Ala Glu Ser Ala
 1 5 10 15

Leu Asp Gln Met Lys Tyr Glu Ile Ala Gln Glu Phe Gly Val Gln Leu
 20 25 30

Gly Ala Asp Ala Thr Ala Arg Ala Asn Gly Ser Val Gly Gly Glu Ile
 35 40 45

Thr Lys Arg Leu Val Ser Leu Ala Glu Gln Gln Leu Gly Gly Tyr Gln
 50 55 60

Lys
 65

<210> 41

<211> 76

<212> PRT

<213> Bacillus cereus

<400> 41

- 83 -

Met Leu Phe Ile Asn Ile Gln Arg Tyr Glu Ser Asp Thr Asn Glu Ile
 1 5 10 15

Leu Ile Ser Ala Thr Thr Ser Thr Ile Glu Gln Met Lys Tyr Glu Ile
 20 25 30

Ala Phe Glu Leu Gly Val Thr Leu Gly Pro Asp Thr Ser His His Leu
 35 40 45

Gln Met Val Arg Ile Gly Gly Glu Ile Thr Lys Arg Leu Val Arg Met
 50 55 60

Ala Glu Lys Gln Leu Thr Gly Gln Tyr Arg Leu His
 65 70 75

<210> 42

<211> 70

<212> PRT

<213> Bacillus stearothermophilus

<400> 42

Met Pro Asn Gln Ser Gly Ser Asn Ser Ser Asn Gln Leu Leu Val Pro
 1 5 10 15

Gly Ala Ala Gln Val Ile Asp Gln Met Lys Phe Glu Ile Ala Ser Glu
 20 25 30

Phe Gly Val Asn Leu Gly Ala Glu Thr Thr Ser Arg Ala Asn Gly Ser
 35 40 45

Val Gly Gly Glu Ile Thr Lys Arg Leu Val Ser Phe Ala Gln Gln Gln
 50 55 60

Met Gly Gly Gly Val Gln
 65 70

<210> 43

- 84 -

<211> 67

<212> PRT

<213> Bacillus thermus

<400> 43

Met	Ala	Asn	Asn	Asn	Ser	Ser	Asn	Gln	Leu	Val	Val	Pro	Gly	Val	Gln
1				5					10					15	

Gln	Ala	Leu	Asp	Gln	Met	Lys	Tyr	Glu	Ile	Ala	Ser	Glu	Phe	Gly	Val
			20					25					30		

Gln	Leu	Gly	Pro	Asp	Ala	Thr	Ala	Arg	Ala	Asn	Gly	Ser	Val	Gly	Gly
		35					40					45			

Glu	Ile	Thr	Lys	Arg	Leu	Val	Gln	Met	Ala	Glu	Gln	Gln	Met	Gly	Gly
	50					55					60				

Tyr	Gln	Lys
65		

<210> 44

<211> 70

<212> PRT

<213> Clostridium bifermentans

<400> 44

Thr	Thr	Asn	Asn	Asn	Asn	Thr	Lys	Ala	Val	Pro	Glu	Ala	Lys	Ala	Ala
1				5					10					15	

Leu	Lys	Gln	Met	Lys	Leu	Glu	Ile	Ala	Asn	Glu	Leu	Gly	Ile	Ser	Asn
			20					25					30		

Tyr	Asp	Thr	Ala	Asp	Lys	Gly	Asn	Met	Thr	Ala	Arg	Gln	Asn	Gly	Tyr
		35					40					45			

Val	Gly	Gly	Tyr	Met	Thr	Lys	Lys	Leu	Val	Glu	Met	Ala	Glu	Gln	Gln
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

- 85 -

50

55

60

Met Ser Gly Gln Gln Arg
 65 70

<210> 45

<211> 64

<212> PRT

<213> Clostridium bifermentans

<400> 45

Ser Thr Lys Lys Ala Val Pro Glu Ala Lys Ala Ala Leu Asn Gln Met
 1 5 10 15

Lys Leu Glu Ile Ala Asn Glu Leu Gly Leu Ser Asn Tyr Glu Ser Val
 20 25 30

Asp Lys Gly Asn Leu Thr Ala Arg Gln Asn Gly Tyr Val Gly Gly Tyr
 35 40 45

Met Thr Lys Lys Leu Val Glu Met Ala Glu Arg Gln Met Ser Gly Lys
 50 55 60

<210> 46

<211> 60

<212> PRT

<213> Clostridium perfringens

<400> 46

Met Ser Lys Ser Leu Val Pro Glu Ala Lys Asn Gly Leu Ser Lys Phe
 1 5 10 15

Lys Asn Glu Val Ala Arg Glu Leu Gly Val Pro Phe Ser Asp Tyr Asn
 20 25 30

Lys Asn Glu Val Ala Asn Glu Met Gly Val Pro Phe Ser Asp Tyr Asn
20 25 30

Met Thr Asn Asn Asn Asn Ser Asn Ser Asn Gln Leu Leu Val Pro Gly
1 5 10 15

- 88 -

Val Gln Gln Ala Ile Asn Gln Met Lys Glu Glu Ile Ala Asn Glu Phe
 20 25 30

Gly Val Asn Leu Gly Pro Asp Ser Thr Ser Arg Ala Asn Gly Ser Val
 35 40 45

Gly Gly Glu Ile Thr Lys Arg Leu Val Arg Gln Ala Gln Ser Gln Met
 50 55 60

Asn Gly Tyr Thr Lys
 65

<210> 51

<211> 67

<212> PRT

<213> Sporosarcina ureae

<400> 51

Met Pro Asn Asn Asn Ser Ser Asn Gln Leu Leu Val Pro Gly Val Gln
 1 5 10 15

Gln Ala Leu Asn Gln Met Lys Glu Glu Ile Ala Ser Glu Phe Gly Val
 20 25 30

Gln Leu Gly Pro Asp Ala Ser Ser Arg Ala Asn Gly Ser Val Gly Gly
 35 40 45

Glu Ile Thr Lys Arg Leu Val Arg Gln Ala Gln Ser Gln Met Asn Gly
 50 55 60

Tyr Thr Lys
 65

<210> 52

<211> 71

- 89 -

<212> PRT

<213> Thermoactinomyces thalpophilus

<400> 52

Met	Ala	Gln	Gln	Gly	Arg	Asn	Arg	Ser	Ser	Asn	Gln	Leu	Leu	Val	Ala
1				5				10						15	

Gly	Ala	Ala	Gln	Ala	Ile	Asp	Gln	Met	Lys	Phe	Glu	Ile	Ala	Gln	Glu
			20				25						30		

Phe	Gly	Val	Thr	Leu	Gly	Ala	Asp	Thr	Thr	Ser	Arg	Ala	Asn	Gly	Ser
		35					40					45			

Val	Gly	Gly	Glu	Ile	Thr	Lys	Arg	Leu	Val	Ser	Leu	Ala	Gln	Gln	Gln
	50					55					60				

Leu	Gly	Gly	Gly	Thr	Ser	Phe
65					70	

<210> 53

<211> 272

<212> DNA

<213> Bacillus subtilis

<400> 53

atggctcaac aaagtagatc aagatcaaac aacaataatg atttactaat tcctcaagca	60
gcttcagcta ttgaacaaat gaaacttgaa atagcttctg agtttggtgt tcaattaggc	120
gctgagacta catctcgtgc aaacggttca gttggtggag aaatcactaa acgttttagtt	180
cgcttagctc aacaaaacat gggcgggtcaa tttcattaat ttatgagggg gataattccc	240
ctctcttttt taagtcttct ctaaattccat ac	272

<210> 54

<211> 823

- 90 -

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> sequence data from SSPC-LAMBDA obtained using primers 13FI and B3
0

<400> 54

ctagttggtc acttcgacgt atcgtctgga actccaacca tcgcaggcag agaggtctgc	60
aaaatgcaat cccgaaacag ttcgcaggta atagtttagag cctgcataac ggtttcggga	120
ttttttatat ctgcacaaca ggtaagagca ttgagtcgat aatcgtgaag agtcggcgag	180
cctggttagc cagtgtctct tccgttgtgc tgaattaagc gaataccgga agcagaaccg	240
gatcaccaaa tgcgtacagg cgtcatcgcc gccagcaac agcacaaccc aaactgagcc	300
gtagccactg tctgtcctga attcattagt aatagttacg ctgcggcctt ttacacatga	360
ccttcgtgaa agcgggtggc aggaggtcgc gctaacaacc tcctgccgtt ttgcccgtgc	420
atatcgggtca cgaacaaatc tgattactaa acacagtagc ctggatttgt tctatcagta	480
atcgacctta ttcctaatta aatagagcaa atccccttat tgggggtaag acatgaccat	540
ggctcaacaa agtagatcaa gatcaacaa caataatgat ttactaattc ctcaagcagc	600
ttcagctatt gaacaaatga aacttgaaat agcttctgag tttgggtgttc aattaggcgc	660
tgagactaca tctcgtgcaa acggttcagt tgggtggagaa atcactaaac gtttagttcg	720
cttagctcaa caaaacatgg gcggtcaatt tcattaaact agtgcaccaa taactgcctt	780
aaaaaaatta cgccccgccc tgccactcat cgcagtactg ttg	823

<210> 55

<211> 566

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> sequence data from SSPC-LAMBDA obtained using primers B54 and B55

- 91 -

<400> 55
 tggttcagcta ctgacggggt ggtgcgtaac ggcaaaagca ccgccggaca tcagcgctag 60
 cggagtgtat actggactag tgaaatcaat aatcaacgta aggcgttcct cgatatgctg 120
 gcgtggtcgg agggaaactga taacggacgt cagaaaacca gaaatcatgg ttatgacgtc 180
 attgtaggcg gagagctatt tactgattac tccgatcacc ctcgcaaact tgtcacgcta 240
 aacccaaaac tcaaatacaac aggcgccgga cgctaccagc ttctttcccg ttggtgggat 300
 gcctaccgca agcagcttgg cctgaaagac ttctctccga aaagtcagga cgctgtggca 360
 ttgcagcaga ttaaggagcg tggcgcttta cctatgattg atcgtggtga tatccgtcag 420
 gcaatcgacc gttgcagcaa tatctgggct tcaactgcgg gcgctgggta tggtcagttc 480
 gagcataagg ctgacagcct gattgcaaaa ttcaaagaag cgggcggaac ggtcagagag 540
 attgatgtat gagcagagtc accgcg 566

<210> 56

<211> 402

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> sequence data from SSPC-LAMBDA obtained using primers T3 and B8

<400> 56
 ctcgatcccg cgaaattaat acgactcact ataggggaat tgtgagcgga taacaattcc 60
 cctctagaaa taattttggt taactttaag aaggagatat accatggctc aacaaagtag 120
 atcaagatca aacaacaata atgatttact aattcctcaa gcagcttcag ctattgaaca 180
 aatgaaactt gaaatagctt ctgagtttgg tgttcaatta ggcgctgaga ctacatctcg 240
 tgcaaacggt tcagttgggt gagaaatcac taaacgttta gtctgcttag ctcaacaaaa 300
 catgggcggt caatttcatt aatttatgag ggggataatt cccctctctt ttttaagtct 360
 tctctaaatc catacctcga gcaccaccac caccaccact ga 402

<210> 57

- 92 -

<211> 23

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> sequence from pB/LF1

<400> 57

ggtaagacat gaagatgccca gaa

23

<210> 58

<211> 30

<212> DNA

<213> Bacillus subtilis

<400> 58

atggctcaac aaagtagatc aagatcaaac

30

<210> 59

<211> 37

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> sequence from pB/SAPB

<400> 59

ggtaagacat gaagatggct caacaaagta gatcaag

37

<210> 60

<211> 37

<212> DNA

- 93 -

<213> ARTIFICIAL SEQUENCE

<220>

<223> sequence from pB/SAPO

<400> 60

ggtaagacat gaccatggct caacaaagta gatcaag

37

CLAIMS:

1. A polypeptide having α/β type small acid-soluble
spore protein (SASP) activity, for use as a medicament
5 for inhibiting or preventing cell growth.

2. A polypeptide according to claim 1, which comprises
the amino acid sequence:

mannnssnsnellvpgaeqaidqmkyeiasefgvnlgadttarangsvgge
10 itkrlvqlaeqqllgggk(SEQ ID NO:1).

3. A polypeptide according to claim 1, which comprises
any one of the amino acid sequences of SEQ ID NO:26 to
SEQ ID NO:52.

15

4. A polypeptide according to claim 2 or claim 3, which
contains mutations which do not reduce the α/β type SASP
activity thereof.

20 5. A polypeptide according to any one of claims 2 to 4,
which contains deletions which do not reduce the α/β SASP
activity thereof.

6. A polypeptide as defined in any one of claims 1 to
25 5, wherein the cell growth comprises bacterial cell
growth.

7. A polypeptide according to claim 6, which is for
use in human therapy.

30

8. A polypeptide according to claim 7, which is for
use in the treatment of topical infections, dental
caries, respiratory infections, eye infections or
localised organ infection.

9. A composition for inhibiting or preventing cell growth comprising a polypeptide as defined in any one of claims 1 to 5 and a delivery system therefor.
- 5
10. Use of a polypeptide having α/β type small acid-soluble spore protein (SASP) activity as a microbial decontaminant.
- 10 11. Use according to claim 10, which comprises treating surface microbial contamination, land remediation or water treatment.
12. Use of a polypeptide having α/β type small acid-soluble spore protein (SASP) activity in the non-therapeutic treatment of vermin to eliminate gut bacteria therefrom.
- 15
13. Use according to any one of claims 10 to 12 wherein the polypeptide comprises the amino acid sequence:
- 20 mannnssnsnellvpgaeqaidqmkyeiasefgvnlgadttarangsvgge
 itkrlvqlaeqqllggggtk(SEQ ID NO:1).
14. Use according to any one of claims 10 to 12 wherein the polypeptide comprises any one of the amino acid sequences of SEQ ID NO:26 to SEQ ID NO:52.
- 25
15. Use according to claim 13 or claim 14 wherein the amino acid sequence contains mutations which do not reduce the α/β type SASP activity thereof.
- 30
16. Use according to any one of claims 13 to 15 wherein the amino acid sequence contains deletions which do not reduce the α/β SASP activity thereof.

17. Use of a polypeptide as defined in any one of claims 1 to 5 as an antimicrobial agent in the treatment of plant material.

5

18. A polynucleotide encoding a polypeptide as defined in any one of claims 1 to 5, for use as a medicament for inhibiting or preventing cell growth.

10 19. A polynucleotide according to claim 18, which comprises DNA.

20. A polynucleotide according to claim 19, which comprises the *sspC* gene from *B subtilis*.

15

21. A polynucleotide according to any one of claims 18 or claim 20, wherein the cell growth comprises bacterial cell growth.

20 22. A polynucleotide according to any one of claims 18 to 21, which is for use in human therapy.

23. A polynucleotide according to any one of claims 18 to 22, which is for use in the treatment of topical
25 infections, dental caries, respiratory infections, eye infections or localised organ infection.

24. A composition for inhibiting or preventing cell growth comprising a polynucleotide as defined in any one
30 of claims 18 to 20 and a delivery system therefor which is capable of targeting a cell.

25. A composition according to claim 24, wherein the delivery system comprises a virus and the polynucleotide is incorporated in the genome of the virus.

5 26. A composition according to claim 25, wherein the virus comprises a bacteriophage which is capable of targeting a bacterium.

27. A composition according to claim 26, wherein the
10 bacteriophage is a non-lysogenic bacteriophage.

28. A composition according to claim 26, wherein the bacteriophage comprises at least one inactivated lysis gene.

15

29. A composition according to claim 28, wherein the at least one lysis gene is inactivated by insertion of the polynucleotide.

20 30. A composition according to any one of claims 25 to 29, wherein the virus has been modified to increase or alter its host-specificity.

31. Use of a polynucleotide encoding a polypeptide
25 having α/β type small acid-soluble spore protein (SASP) activity as a microbial decontaminant.

32. Use according to claim 31, which comprises treating surface microbial contamination, land remediation or
30 water treatment.

33. Use of a polynucleotide encoding a polypeptide having α/β type small acid-soluble spore protein (SASP)

activity, in the non-therapeutic treatment of vermin to eliminate gut bacteria therefrom.

34. Use of a polynucleotide according to any one of
5 claim 31 to 33 wherein the polypeptide comprises the amino acid sequence:

mannnssnsnellvpgaeqaidqmkyeiasefgvnlgadttarangsvgge
itkrlvqlaeqqllgggtk(SEQ ID NO:1).

10 35. Use of a polynucleotide according to any one of claims 31 to 33 wherein the polypeptide comprises any one of the amino acid sequences of SEQ ID NO:26 to SEQ ID NO:52.

15 36. Use of a polynucleotide according to claim 34 or claim 35 wherein the amino acid sequence contains mutations which do not reduce the α/β type SASP activity thereof.

20 37. Use of a polynucleotide according to any one of claims 34 to 36, wherein the amino acid sequence contains deletions which do not reduce the α/β SASP activity thereof.

25 38. Use of a polynucleotide according to any one of claims 31 to 37 wherein the polynucleotide comprises DNA.

39. Use of a polynucleotide according to claim 38 wherein the polynucleotide comprises the sspC gene from
30 *B. subtilis*.

40. Use of a polynucleotide as defined in any one of claims 18 to 20, as an antimicrobial agent in the treatment of plant material.




FIGURE 1




FIGURE 2




FIGURE 3





FIGURE 4



5/13

FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11

12/13




Figure 12

13/13




FIGURE 13

